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 RNA Polymerase (Pol) III transcribes small noncoding RNAs (e.g., 
tRNAs) important for translational capacity.  Maf1 is a repressor of Pol III 
conserved from yeast to human, required for repression of Pol III in response to 
multiple environmental stresses, such as nutrient deprivation.  Interestingly, Maf1 
is a phosphoprotein, being phosphorylated in good growth conditions and 
dephosphorylated in poor growing conditions.  The phosphatase acting on Maf1 
has not been determined.  I investigated the identity of the phosphatase in yeast 
Saccharomyces cerevisiae using a genetic Maf1-Pol III fusion construct in 
combination with molecular and biochemical assays.  I queried members of 
Protein Phosphatase 2A and 4 complexes (PP2A and PP4, respectively) for their 
role in dephosphorylation of Maf1 and determined that PP4—containing Pph3 
and Psy2, together with accessory factors Rrd1 and Tip41—is the major Maf1 
phosphatase, acting in response to multiple stresses.  Maf1 interacts with Pph3 
in vivo, and biochemical purification of TAP-tagged Pph3-bound complex shows 
activity on purified, endogenously phosphorylated Maf1 in vitro, suggesting that 
PP4 is a direct phosphatase of Maf1.   
 In human cells, regulation of Pol III also involves chromatin regulation, not 
apparent in studies of Pol III in yeast.  The full repertoire of Pol III-transcribed 




transcriptome in human (HeLa) cells by chromatin immunoprecipitation (ChIP), 
coupled with microarray (ChIP-array) or high throughput sequencing (ChIP-seq), 
for Pol III subunit Rpc32, and Pol III transcription factors Brf1, Brf2 and TFIIIC63.  
I also determined the Pol III transcriptome in other cell types to address the 
possibility of cell type-specific activation of Pol III genes.  Although many active 
Pol III genes were shared between all cell types assayed, a large number of 
genes were differentially enriched with Pol III.  I compared enrichment of Pol III 
with chromatin modifications, transcription factors, and Pol II ChIP-seq profiles 
and found a significant correlation for active Pol III genes with active chromatin 
modifications and occupancy of transcription factors and Pol II.  These results 
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RNA Polymerase III Target Gene Products and Functions 
Biology of Known Pol III Products 
RNA synthesis in eukaryotes is conducted by three RNA Polymerases, 
termed Pols I, II, and III, with an additional two polymerases (IV and V) present in 
plants.  Pol III transcriptional activity is required for many basic cellular functions, 
as well as regulatory processes in the cell.  All transcripts produced by Pol III are 
short (<400bp) and of a noncoding nature.  This short length is partially 
determined by the frequency of Pol III terminators in the genome1 (i.e., a stretch 
of !4 thymine residues).  These noncoding RNAs (ncRNAs) play structural or 
catalytic roles in ribonucleoprotein particles (RNPs).  As a group, these RNPs 
have a myriad of functions in cellular biology.  Pol III transcribes small ncRNAs 
important for translational capacity2, such as the 5S rRNA, RNase P, RNase 
MRP, and all tRNAs (and snoRNAs in C. elegans3).  In addition, Pol III also 
transcribes a growing list of ncRNAs with alternative functions4, providing 
interesting connections to the biology of splicing (U6), viral RNAs (VA-I/II), 
microRNAs, DNA repeat-derived RNAs (SINEs, including MIR and Alu 
elements), neuronal disease and protein translation (BC200), Pol II 
! ! !! ! 2 !
transcriptional regulation (7SK, BC2), spermatogenesis (BC1), and multidrug 
resistance (Vault).   
Potential to Identify Novel Pol III Targets 
In the past decade, there has come an increasing awareness of the fact 
that a large fraction of the human genome is transcribed to some degree5.  In 
2007, based on methods largely reliant on various forms of microarray 
techniques and querying the Encyclopedia of DNA Elements (ENCODE) regions 
of the human genome (comprising ~30Mb total, or about 1% of the human 
genome), it was extrapolated that 74% of the genome was transcribed if two 
independent technologies were considered, or 93% if only one technology is 
considered6.  Most of the novel transcripts identified in large-scale studies have 
no potential to be translated into protein7, and are defined as “noncoding” RNAs.   
Pol III is well-known for its production of many different types of ncRNAs4.  
In addition to the known functional ncRNAs, there have also been reported 
several microRNAs (miRNAs) transcribed by Pol III whose function is as yet 
unknown8.  Generally, miRNAs are involved in post-transcriptional regulation of 
protein expression, so the potential for Pol III transcripts in regulating specific Pol 
II genes is intriguing.  These miRNAs are reportedly driven by Alus, short 
interspersed element (SINE) class repeats.  An Alu repeat contains an A and a B 
box that allow for TFIIIC binding and Pol III recruitment.  It is predicted that 
approximately 10% of the known miRNAs may be transcribed by Pol III based on 
their proximity to Alu repeats8.  In 2007, one report showed the discovery of a 
functional type 3 promoter Pol III gene starting from a bioinformatics search for 
! ! !! ! 3 !
Pol III promoter elements in the human genome9.  Also in 2007, another Pol III-
transcribed gene was discovered—CBL3—which may be a novel vault RNA, or it 
could be a miRNA10.  Finally, in 2007, an entirely new family of Pol III genes was 
discovered, called small NF90-associated RNAs (snaRs)11.  Thus, the repertoire 
of Pol III genes continues to expand.   
The human transcriptome study by Affymetrix identified many unannotated 
transcribed RNA fragments (transfrags) in human cells12.  Their study catalogued 
RNA expression genomewide, covering the nonrepeat human genome 
(approximately 45% coverage of the human genome sequence), tiled at an 
average of 5 bp resolution for seven human cell lines.  Included in their study 
was a comparison of long (>200 nt) versus short (<200 nt) RNAs, cytoplasmic vs. 
nuclear RNAs and sense vs. antisense short RNAs.  Their findings showed that 
roughly half of the transfrags corresponded to annotated genes and expressed 
sequence tags (ESTs), while the other half represented unannotated transfrags.   
Given that new human Pol III genes have been discovered as recently as 2007, 
and that unbiased whole genome discovery technology has not yet probed into 
repeat regions of the genome, it is highly likely that other Pol III target genes 
exist among unannotated regions of the genome, which could be part of new 
RNPs, miRNAs, or another class of ncRNA.   
Pol III Basal Transcription Machinery and Promoter Types 
Extensive work on Pol III target genes in yeasts, invertebrates, and 
vertebrates has revealed the factors required for directing Pol III to target 
genes1,13,14.  The three ‘Types’ of Pol III genes in humans (Fig. 1.1) have been 
! ! !! ! 4 !
!
Figure 1.1  Pol III promoter types.  Pol III–transcribed genes are classified into 
three types on the basis of sequence elements and transcription factors. IE, 
intermediate element; DSE, distal sequence element; PSE, proximal sequence 
element.  Adapted from ref. 19 
defined based on the presence and positions of cis regulatory elements, and the 
requirement for particular basal or accessory transcription factors.  Briefly, 5S 
rRNA is the sole Type 1 gene, uniquely requiring TFIIIA.  Type 1 and Type 2 
genes both require TFIIIC, a basal factor and targeting complex that recognizes 
gene-internal A-box and B-box elements at Type 2, but not Type 1 genes. The 
TFIIIB complex includes the TATA-binding protein (TBP), needed for 
TATA/promoter recognition and Pol III initiation.  Type 2 and 3 genes utilize 
alternative assemblies of TFIIIB: BRF1 for Type 2 and BRF2 for Type 3 genes.  
Type 3 genes lack an internal A- or B-box, and lack reliance on TFIIIC, relying 
instead on upstream proximal and distal sequence elements (PSE and DSE) and 
specific factors (Oct1, SNAP, others) for targeting.  Notably, Type 3 Pol III 
! ! !! ! 5 !
promoters resemble Pol II genes in their architecture, which utilizes upstream 
regulatory elements rather than gene-internal elements. 
Pol III Is Implicated in Cancer Progression 
Pol III is overactive in many types of cancer.  For over one hundred years, 
it has been understood clinically that cancer tissue often exhibits enlargement of 
the nucleoli15.  It is in the nucleolus of a nucleus that ribosomal DNA (rDNA) is 
transcribed into ribosomal RNA (rRNA) and where ribosomes are assembled 
from their protein and RNA parts.  It is also the location of tRNA transcription by 
Pol III and tRNA processing16,17.  This enlargement of nucleoli is suggestive of 
overactive Pol I and III, since nucleoli size has been correlated with the rate of 
rDNA transcription18.  Once molecular characterization of cancer became 
possible, it was also determined that many Pol III factors and target gene 
products are overexpressed in cancer.  Multiple members of TFIIIC are 
overexpressed in ovarian cancer20.  TFIIIB members Bdp1 and Brf1 have been 
found overexpressed in cervical cancer21.  Overexpression of Pol III targets 
including tRNAs, 7SL, rRNA, Alu, and BC200 have been reported in multiple 
types of cancer21,22.  Whether overexpression of any these products plays a role 
in cancer outside of generally accelerating cell growth is not known, although one 
study reports that specific types of tRNAs isotypes are consistently 
overexpressed in breast cancer, and that these isotypes show a statistically 
significant enrichment in codons required for cancer-related gene translation but 
not housekeeping genes23.  To support the idea that overexpression of these 
transcripts can support more rapid growth, induced overexpression of tRNAiMet, 
! ! !! ! 6 !
the methionine that initiates translation of messenger RNA (mRNA) in mouse 
fibroblasts leads to higher overall rate of protein synthesis, proliferation, and 
oncogenic transformation22. In contrast, one small family of Pol III gene products 
has shown a direct clinical relationship with cancer: the Vault RNAs (or HVG 
RNAs).  The expression and overexpression of Vault RNAs and their associated 
proteins has been associated with multidrug resistance (MDR) in cancer 
treatment, against chemotherapeutic drugs such as mitoxantrone and 
doxorubicin24-27!and is associated with poor outcome in multiple types of 
cancers28,29.  Importantly, Pol III!is also a target of many tumor suppressors, 
including direct repressive interaction of TFIIIB by Retinoblastoma protein (Rb) 
and p5330-33, as well as indirect repression by phosphatase and tensin homolog 
(PTEN) via the phosphoinositide 3-kinase (PI3K) signaling pathway34. Pol III is 
also a target of oncogenes, including direct activating interaction by the 
oncogenic Myc protein35.  Together, these data suggest that deregulation of Pol 
III might be one step in the process that could lead to cancer and that Pol III 
might be a effective target for therapeutic intervention.  In addition, a better 
understanding of the breadth of Pol III targets, as well as the RNP complexes of 
which they are a part could help us to understand what other potential 
mechanisms there could be for deregulated Pol III to lead to cancer progression.  
Since several novel Pol III target genes have recently emerged (e.g., snaR family 
of ncRNAs), it will be interesting to determine their function and to determine 
whether they too might be involved in cancer progression.   
! ! !! ! 7 !
Chromatin Regulation of Pol III Transcription 
Coordinate Regulation of RNA Polymerases 
Transcription of the protein synthetic machinery (PSM) by all three RNA 
Polymerases coordinately responds to nutrient availability and growth conditions 
(Fig. 1.2).  The RNA Polymerases work together to produce the PSM, accounting 
for ~80% of nuclear transcription in proliferating cells36.  The transcripts produced 
by these polymerases are all required for protein synthesis, including ribosomal 
RNAs (mostly transcribed by Pol I except for 5S rRNA, which is transcribed by 
Pol III), ribosomal protein genes (Pol II), and tRNAs (Pol III).  In response to 
multiple stresses, such as nutrient availability and DNA damage, repression of all 
components of PSM is observed.  Because of the high energy requirement of 
PSM production, it makes sense that all three polymerases would be 
coordinately repressed in poor growth conditions in order to conserve energy 
until conditions are more favorable for growth.  In this study I will focus on RNA 
Polymerase III regulation: what is already known, and how I have investigated 
this further.   
Pol III Activity Default States in Yeast and Human  
To better understand Pol III regulation, it is important to understand the 
default state for Pol III transcription and to know what differences there are for 
yeast and human Pol III.  Unlike Pol II transcription, which requires regulated, 
gene-specific activation of its targets, Pol III transcription in yeast has a “default 
on” state.  In a genome-wide Pol III ChIP-on-chip study in S. cerevisiae, the Pol 
! ! !! ! 8 !
III machinery was found to be enriched at all predicted Pol III genes (275 tRNA 
genes, in addition to 5S rDNA, SNR6, SCR1, and RPR1), although there was  
some variability in the level of enrichment at different genes38.  When growth 
conditions are poor and the demand for protein synthesis is decreased, 
attenuation of the Pol III system requires the master repressor Maf1.  Although 
Maf1 plays a conserved role in metazoans, it appears there are other levels of 
















Wsc proteins, PKC TORC1 kinase Mec1/Tel1
Common mediator of repression?
Rap1 Maf1
Pol I Pol II Pol III
Figure 1.2 All RNA Polymerases are coordinately repressed in cellular stress.  
Adapted from ref. 37.!!!!
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are 513 predicted tRNA genes in the contiguous human (hg18) genome, not 
including tRNA pseudogenes (109 total), but there is evidence that there is 
fractional usage in different cell types.  This has been shown for tRNA genes as 
well as other Pol III targets.  It was shown that particular tRNAs are 
overexpressed in brain tissue39, and the snaR family of ncRNAs are specific to 
testes11.  This is also true in other metazoans. In both human and mouse, BC200 
shows neuron-specific expression40.  In Xenopus, an oocyte-specific 5S rRNA is 
overexpressed during oogenesis and early embryogenesis41.  In Bombyx mori, 
tRNAAla is overexpressed specifically in the silk gland42, likely to aid in producing 
silk fibroin protein, which is a 391 kDa protein that is 30% alanine by 
composition.  One potential cause for a differential use Pol III targets in 
metazoans compared to yeast is the dynamic regulation of the chromatin 
environment of genes throughout the development of a multicellular organism, 
and advanced mechanisms of producing repressive chromatin not present in 
yeast. 
Chromatin Effects on Gene Expression 
 “Chromatin” refers to the DNA in the nucleus of a cell plus the proteins 
that are bound to the DNA.  The proteins associated with DNA make up part of 
the packaging of the DNA, and they provide information content about the genes 
that are located there as well.  Inside the nucleus of a cell, DNA is packaged into 
a higher order structure to allow organized retrieval of information (Fig. 1.3).  The 
information that is needed by the cell consists of genes, which need to be  
  
! ! !! ! 10 !
Figure 1.3 Histone code.  DNA in the nucleus of a cell is packaged with 
histone proteins as chromatin.  Histone tails can receive modifications, which 
represent active and repressed chromatin.  Ac, Acetyl; Me, Methyl; P, 
Phosphate; Ub, Ubiquitin. Reprinted by permission from Macmillan Publishers 
Ltd: Nature Reviews Cancer, ref. 50, copyright 2006.  !!
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available for expression at the appropriate time and place.  At the basic level, a 
nucleosome consists of DNA wrapped around a histone protein core.  This 
“beads on a string” structure of repeating nucleosomes is organized into larger 
fibers and ultimately into a fractal-like higher order structure that allows opening 
of individual sections without interfering with the rest of the structure43,44.  Some 
of the information that is contained in chromatin is information about which genes 
need to become activated or repressed, and within each gene region, chromatin 
provides information about where transcription should start, where splicing 
should occur, etc.  Much of this information content is stored in the form of 
histone modifications45.  The amino acids that make up amino-terminal histone 
tails can be modified on their functional groups in certain ways to act as a flag to 
other factors in the cell, such as chromatin remodelers and modifiers.  For 
example, histone H3 is often modified by trimethylation at lysine 4 (H3K4me3) to 
signal to Pol II where to begin transcription at active genes46.  Transcriptionally 
active chromatin, or “euchromatin,” is characterized by positive histone 
modifications, including H3K4me3, as well as histone acetylation, which can be 
recognized by bromodomain-containing proteins such as the RSC chromatin 
remodeler47.  Transcriptionally inactive chromatin, or “heterochromatin,” displays 
modifications that are repressive, such as DNA methylation, H3K27me3, 
H3K36me3, and H3K9me3, which can recruit repressor complexes such as 
Polycomb (recruited by H3K27me348), histone deacetylases  (HDACs; e.g., 
binding of heterochromatin protein 1 (HP1) to H3K9me3 allows recruitment of 
HDAC4 and HDAC549), or other co-repressors.   
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Yeast Chromatin Lacks Many Repressive Mechanisms  
While all of these types of modifications are present in human cells, many 
of these are greatly simplified or absent in yeast.  Absent from yeast are DNA 
methylation, H3K27me3, Polycomb, and H3K9me3.  This reduces the ability of 
yeast to form large domains of repressive chromatin.  Instead, repression occurs 
on a gene-by-gene basis where DNA-binding transcription factors (TFs) recruit 
histone deacetylases to inactive a particular gene.  For example, during 
sporulation, many genes are repressed by binding of either Sum1 or Ume6 TFs 
in the promoter, which recruit Hst1 or Rpd3 HDACs, respectively51,52.  It is quite 
reasonable that yeast would not have the ability to create large repressive 
chromatin domains, since the gene density is quite high, with a very short 
average distance between genes compared to metazoans.  In addition, the yeast 
genome has a much smaller amount of “junk” DNA compared to the human 
genome.  The “junk” DNA in the human genome is made up largely of ancient 
retrotransposons53 but includes some that could potentially be 
retrotranspositionally active if they were allowed to be expressed, so 
mechanisms have been developed to repress their transcription.  In the absence 
of most repressive mechanisms, the yeast genome is considered much more 
permissive to transcription than that of higher eukaryotes.  One other evidence of 
highly permissive transcription is the characteristically unstable nucleosome 
particle present in yeast compared to higher eukaryotes54-57.  With less stable 
nucleosomes, disassembly of a nucleosome to allow gene activation is much 
easier to accomplish.  In light of all of these differences between 
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human/metazoan and yeast, it is very likely that chromatin regulation is a layer of 
Pol III regulation that could be seen in human cells although absent in yeast.   
In summary, it appears that human Pol III is regulated on two levels: 1) 
access to Pol III genes via chromatin regulatory mechanisms and 2) strength of 
transcription, via Maf1; yeast Pol III appears to be regulated primarily by the latter 
mechanism.   
Maf1-Dependent Regulation of Pol III 
Regulators of Pol III Present in Human but not in Yeast 
In addition to the added complexity of tissue-specific expression of Pol III 
targets and chromatin regulatory mechanisms, there are also other activators 
and repressors of Pol III in metazoans not present in yeast.  As mentioned 
previously, many of these repressors are tumor suppressors, which could be why 
some Pol III targets are overexpressed in cancers that have certain compromised 
tumor suppressor genes.  The relationship of these metazoan regulators of Pol III 
to Maf1 is not known, although it is clear that repression of Pol III in response to 
environmental stress is dependent on Maf1 in both yeast and humans.   
Identification of Maf1 Involvement in Pol III Regulation 
Maf1 was first identified in yeast Saccharomyces cerevisiae and 
conserved homologs have been found in eukaryotes from yeast to human.  The 
maf1 strain was identified as a mutant that caused an antisuppression phenotype 
in an ade2-1 SUP11 background, caused by an overproduction of tRNAs, 
suggesting that Maf1 may be involved in Pol III transcription58.  
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There are several lines of evidence that prove that Maf1 is the master 
repressor of Pol III.  Yeast maf1 mutant cells produce a higher basal level of 
tRNAs than WT cells and it was reported that mutations in the large subunit of 
Pol III—Rpc160—that lower tRNA levels rescue the phenotype of maf1 mutant 
cells, demonstrating that Maf1 plays a role in regulating Pol III59.  Mutations in the 
large subunit of Pol III—Rpc160—that lowered tRNA levels could rescue the 
phenotype of maf1 mutant cells, suggesting that Maf1 might play a role in 
regulating Pol III59.  Maf1 interacts in vivo with several subunits of the Pol III 
machinery, including Pol III components Rpc160, Rpc34, and Rpc82, as well as 
TFIIIB component Brf159-61.  There is also reported a direct interaction of Maf1 
with the N-terminus of Rpc160 in vitro, suggesting that this is a subunit to which 
Maf1 binds within the complex62, further verified by the crystal structure of Maf1 
bound to Pol III63.  Importantly, all repression signals for Pol III appear to 
converge on Maf1, including response to nutrient deprivation, DNA damage, 
oxidative stress, and cell wall stress64,65.  Maf1 is not required for repression of 
ribosomal protein genes or Pol I-encoded ribosomal RNAs, suggesting that Maf1 
is specifically dedicated to repression of Pol III64.  In summary, the data indicate 
that Maf1 specifically represses Pol III transcription in response to multiple 
stresses by direct interaction with the Pol III machinery. 
Mechanism of Maf1-dependent Repression of Pol III 
Previous work has elucidated many of the factors involved in regulating 
Maf1.  Maf1 is a serine-rich protein that is phosphorylated and mostly 
cytoplasmic in favorable growth conditions61.  Phosphorylation by Sch9 and PKA, 
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and nuclear export by Msn5 are important for maintaining its cytoplasmic 
localization66-68. Upon stress, Maf1 is dephosphorylated, it accumulates in the 
nucleus, and it becomes highly enriched at Pol III target genes as shown by 
whole genome ChIP-on-chip studies61,62.   In vitro systems have demonstrated 
that Maf1 can block recruitment of TFIIIB to preformed TFIIIC-DNA complexes60.  
However, in vivo, Maf1 is also able to repress Pol III at a time when all three 
subcomplexes remain on DNA (TFIIIB, TFIIIC, and Pol III).  The resolution of 
these data can be explained by two phases of repression: acute phase (< 30 
min.), in which Maf1 associates with Pol III on DNA and represses transcription, 
and the prolonged phase, in which TFIIIB and Pol III are displaced from DNA and 
recruitment of new active Pol III complexes is inhibited.   
Both molecular and genetic data support the idea that phosphorylation is a 
key regulatory modification for Maf1.  A previous study in our lab established that 
Maf1 migration in SDS-PAGE is faster in stressed cells versus unstressed cells, 
due to loss of phosphate61.  Dephosphorylation of Maf1 is correlated with its 
nuclear localization and only the hypophosphorylated form of Maf1 interacts with 
Pol III, suggesting that dephosphorylation is important for repression.  To test 
whether dephosphorylation was required for repression, conserved residues of 
Maf1 were mutated in order to create mutants that were not dephosphorylatable.  
These constitutively phosphorylated mutants were also defective for nuclear 
localization, association with Pol III, and repression of Pol III transcription.  These 
results suggest that dephosphorylation of Maf1 is a key step in repression of Pol 
III.  Since Pol III specifically interacts with the hypophosphorylated form of Maf1, 
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it is likely that the major role of Maf1 dephosphorylation is in the acute phase of 
repression61. 
Identifying the Phosphatase of Maf1 
Since Maf1 dephosphorylation is a common mechanism in all reports of 
Maf1-dependent repression of Pol III to date, the identity of the phosphatase(s) is 
an intriguing question.  Since Pol III repression occurs in a Maf1-dependent 
manner in response to multiple cellular insults, representing multiple signaling 
pathways, it could be that there are multiple phosphatases acting on Maf1 in 
response to the different stress treatments.  Or, alternatively, there could be one 
phosphatase that accounts for the majority of Maf1 dephosphorylation in 
response to all Pol III-repressive stresses.  Many phosphatases in yeast have 
been tested for their requirement in dephosphorylation of Maf1, including Sit4, 
Yhv1, Ppz1, His2, Msg5, and Cdc14, showing no effect61, but there is one report 
strongly pointing to the PP2A family of serine/threonine phosphatases as playing 
a role62, discussed in detail below.  Although human Maf1 is also regulated by 
phosphorylation69-73, no study has sought to the identity of the phosphatase of 
human Maf1.  Perhaps studies in yeast will again be fruitful here in directing 
future studies of Pol III regulation, as has been the case in the history of Maf1 
and Pol III.   
PP2A Family Phosphatases 
The PP2A family of phosphatases are interesting as a group, since they 
are regulated by the target of rapamycin complex (TOR), and specific inhibition of 
! ! !! ! 18 !
TOR nutrient signaling with the macrolide antibiotic rapamycin induces rapid 
inhibition of Pol III transcription74.  The regulation of PP2A phosphatases by TOR 
suggests a possible mechanism of integrating nutrient availability and other 
stresses to dephosphorylation of Maf1.  Regulation of PP2A family phosphatases 
by TOR occurs via the protein Tap42.  Tap42 interacts with the PP2A family 
catalytic subunits Pph21, Pph22, Pph3, and Sit475-77 (Fig. 1.4A) and this 
interaction is reinforced by TOR phosphorylation of Tap4278.  Upon inhibition of 
TOR by the drug rapamycin or by poor nutrient source, the phosphatases 
become active, probably by dissociating from Tap42 and associating in their 
respective holoenzymes79 (Fig. 1.4B, C).  While Sit4 is not involved in Pol III 
repression37,61, a potential role for Pph21/22 or Pph3 has been reported62.  The 
triple catalytic mutant of phosphatases pph21!, pph22-ts, and pph3! was shown 
to be defective for Maf1 dephosphorylation and Pol III repression.  These three 
have frequently been reported as alternative catalytic subunits of the PP2A 
phosphatase complex (see below), therefore, the conclusion of a former study 
was that PP2A is the phosphatase of Maf1.  However, the PP2A scaffold and 
catalytic mutants tpd3! and pph21! pph22!, respectively, are not defective for 
Maf1 dephosphorylation, initially raising the possibility that Pph3 may be the 
phosphatase of Maf1 rather than PP2A61.   
Confusion Between PP2A and PP4 
I digress briefly to discuss potential reasons for the perpetuation of the 
idea that yeast PP2A contains three alternative catalytic subunits.  The basis for 
calling the three mentioned phosphatases (Pph21, Pph22, Pph3) alternative 
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Figure 1.4 PP2A family phosphatases in yeast. (A) Canonical view of nutrient-
responsive TORC1 regulation of PP2A family phosphatases. Phosphatases 
Pph21, Pph22, Pph3, and Sit4 (but not Ppg1) interact with a repressor, Tap42.  
This interaction is enhanced by TORC1.  When interacting with Tap42, the 
phosphatase subunits are likely excluded from their respective holoenzymes.  
TORC1 complex can be inhibited by rapamycin or nutrient deprivation (B) PP2A 
holoenzyme with alternative subunits specified.  (C) PP4 holoenzyme. !!!!!!!!!!!
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catalytic subunits of PP2A stems from early work by Ronne et al. in defining the 
phenotype of these mutants80.  The single mutant of Pph21 or Pph22 produces 
no detectable growth phenotype, consistent with the functional redundancy 
between the two genes. A double pph21!pph22! mutant has a severe slow 
growth phenotype and the combined disruption of Pph21, Pph22, and Pph3 is 
lethal.  Some have interpreted this result, in combination with the sequence 
similarity between the proteins, to mean that Pph3 is an alternative catalytic 
subunit of PP2A (e.g., ref. 81).  This is not an acceptable conclusion, according 
to the authors of the paper in which the disruption was created.  The authors are 
clear that the Pph3 is not homologous with PP2A: “these two genes [PPH21 and 
PPH22] encode true homologs of PP2A in budding yeast".The PPH3 protein is 
not closely related to PPH1/SIT4, PPH21 or PPH22”80.  And with reference to the 
death in the triple mutant, they state the following:  
This finding is surprising for two reasons.  First, it differs from the results of 
Sneddon et al., who found that spores disrupted for both PPH21 and 
PPH22 either fail to germinate or arrest as microcolonies with less than 32 
cells. Second, the sequence of PPH3 does not suggest that it is a PP2A 
homolog.  Instead, it belongs to the group of PP2A-like proteins that 
includes PPH1, PPV, and PPX. We think that these results should be 
interpreted as a partial suppression of the PP2A deficiency by PPH3, even 
though the latter enzyme probably has a function distinct from that of 
PP2A80. 
 
There are nearly a dozen papers that have referred to Pph21, Pph22 and Pph3 
as orthologs of mammalian PP2A and which state (or strongly imply) that all 
three are alternative catalytic subunits of PP2A, most of which have cited one of 
two papers as evidence: i.e., papers citing Ronne et al. (1991)62,65,81-85; papers 
citing Evans and Stark (1997)62,81,86-88.  Evans and Stark are also clear in their 
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understanding that though they were working with strains that have mutations in 
PPH21, PPH22, and PPH3, that Pph3 is not a part of PP2A, evidenced by 
phrases such as “we investigated the influence of SSD1-v1 on growth in the 
absence of both the PP2A C subunits and Pph3p”89.  With the thoughts of the 
authors of these seminal papers in mind, it is surprising to realize that many who 
have investigated Pph3 since the time these papers were published have 
interpreted their findings to mean the opposite, or have misinterpreted these 
papers.  This is part of the reason why the phosphatase complex important for 
dephosphorylation of Maf1 was unknown until our study.   
Protein Phosphatase 4 
Instead of Pph3 being a part of PP2A, there is an expanding body of 
evidence that shows that Pph3 is part of an evolutionarily conserved 
phosphatase complex, Protein Phosphatase 4 (PP4).  Pph3 homologs have been 
studied in amoeba, budding yeast, human, worms, and fruit flies and found to 
have a conserved role in the regulation of the DNA damage response90-92.  In 
addition, interaction of Pph3 (or its homologues) with PP4-specific subunits has 
been shown in human, S. cerevisiae, D. discoideum, and C. elegans90-92.   
It is becoming clear that PP4 is a complex that is involved in the cellular 
response to environmental stress in yeast.  The Target of Rapamycin complex 1 
(TORC1) is a kinase complex that regulates PP2A family phosphatases, 
including PP2A, PP4, and PP6 in response to environmental nutrient status.  
Inhibition of TORC1 in yeast leads to G0 stationary phase, since the cells “think” 
they are deprived of nutrients74.  Stresses that inhibit TORC1, such as starvation 
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of good sources of amino acids, nitrogen, or carbon93, as well as the antibiotic 
rapamycin, which specifically inhibits TORC1 activity, are also known to repress 
Pol III transcription, implicating the Tor pathway in regulation of Pol III37.  Since 
Tap42 inhibition of PP2A family phosphatase subunits is sensitive to TORC1 
activity, all PP2A family phosphatases are prime candidates for Maf1-dependent 
repression of Pol III in response to nutritional status.  In addition, pph3" cells are 
resistant to rapamycin-induced growth arrest, suggesting that PP4 activity plays 
a role in the starvation-mediated growth arrest that is not redundant with other 
PP2A family phosphatases94.  It is possible that one function of PP4 in 
rapamycin/starvation-induced growth arrest is repression of Pol III transcription.   
As already mentioned, PP4 plays a role in DNA damage, which is another 
cellular perturbation that causes Pol III repression.  PP4 dephosphorylates 
Rad53 and #H2AX in order to recover from the intra-S cell cycle checkpoint 
induced by DNA damage95,96.  Recent data show that in the nuclear exportin 
msn5" mutant strain, Maf1 is constitutively localized in the nucleus but still 
requires dephosphorylation to repress Pol III67.  This suggests that the 
phosphatase of Maf1 must be capable of localizing to the nucleus during stress.  
Both of the known substrates of yeast PP4 are nuclear proteins97, and PP4 is 
activated towards these substrates in DNA damaging conditions, putting PP4 in 
the proper time and place for filling the role of a Maf1 phosphatase in yeast.  
Dissertation Overview 
In this study, I have characterized the Pol III transcriptome in human cells 
and have investigated mechanisms of Maf1 regulation of Pol III in yeast.   
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I characterized the Pol III transcriptome in an unbiased, genome-wide 
fashion by chromatin immunoprecipitation (ChIP) of multiple subunits of the Pol 
III machinery, coupled with microarray or high-throughput sequencing 
technology.  This work is presented in Chapter 2 as previously published in 
Nature Structural and Molecular Biology19.  ChIP is a technique used to identify 
binding sites of proteins in the genomic DNA of an organism.  Briefly, cells are 
cross-linked with formaldehyde to covalently link DNA to its associated proteins; 
the proteins are immunoprecipitated from extracts (along with DNA) using 
antibodies specific to the protein; DNA is isolated, amplified, and subjected to 
competitive hybridization microarray or high-throughput sequencing to determine 
bound regions. Pol III ChIP on a scale as large as this had never been previously 
performed.  I used whole genome microarrays (tiled at ~150 bp resolution, 
consisting of ten 1 million feature arrays) representing the nonrepeat genome for 
Pol III (RPC32) ChIP-on-chip.  In addition, ChIP DNA bound by Pol III (RPC32), 
Brf1, Brf2, or TFIIIC63 was subjected to sequencing.  Using two platforms, I was 
able to comprehensively determine the binding locations of the Pol III machinery 
and catalogue active genes in multiple cells lines.  I also determined Pol III 
occupancy relationships with chromatin status in two cell types to determine 
correlations between active Pol III genes and positive chromatin modifications, 
transcription factor occupancy, and Pol II occupancy.   
In my mechanistic study in yeast, I have investigated the basis of Maf1 
dephosphorylation in repression of Pol III.  This work is presented in Chapter 3 
as a manuscript in preparation for publication.  I verified the hypothesis that Pph3 
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is the catalytic subunit of PP4 and not PP2A in yeast, and (more importantly) that 
PP4 is the major phosphatase of Maf1 in response to multiple stress pathways in 
yeast.  I used strains genetically disrupted for components of PP4 and PP2A to 
test for ability for Maf1 dephosphorylation and Pol III repression.  I purified PP4 
from yeast and tested for its ability to dephosphorylate Maf1 in vitro.  I also 
developed a novel Maf1-Pol III fusion protein that has proven useful in identifying 
PP4 components and associated factors and may be a valuable tool in 
elucidating other components of the pathway of Pol III repression. 
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RNA synthesis in mammals is conducted by three RNA polymerases, 
termed Pol I, Pol II and Pol III, with an additional two polymerases 
(IV and V) present in plants. Pol III transcribes small noncoding 
RNAs important for translational capacity1, such as the 5S ribo-
somal RNA, RNase P, RNase MRP and all tRNAs. In addition, there 
is a growing list of noncoding RNAs with alternative functions that 
Pol III is known to transcribe2, which connects this polymerase to the 
biology of splicing (U6), viral RNAs (VA-I and VA-II), microRNAs 
(miRNAs), DNA repeat–derived RNAs (short interspersed nuclear 
elements, including mammalian-wide interspersed repeat (MIR) 
and Alu elements), neuronal disease and messenger RNA translation 
(BC200), Pol II transcriptional regulation (7SK, BC2), spermato-
genesis (BC1) and multidrug resistance (Vault). However, the full 
repertoire of Pol III genes in the human genome is not known and 
must be determined in multiple cell types to understand the full scope 
of Pol III biology. Also of high interest is Pol III regulation—whether 
the Pol III transcriptome is constitutive or instead highly regulated, 
and if it is regulated, by what mechanism. For example, there are 513 
predicted tDNAs (genes encoding tRNAs) in the contiguous genome 
(hg18 human genome assembly), not including tRNA pseudogenes 
(172 total), but their fractional usage in different cell types is entirely 
unknown. Also, high levels of Pol III transcription and tRNA pools 
are correlated with the growth of cancer cells3,4. A better understand-
ing of Pol III dynamics and regulation is needed for understanding 
normal Pol III biology and its misregulation in cancer and disease.
Extensive work on Pol III genes in yeasts, invertebrates and verte-
brates has revealed the factors required for directing Pol III to target 
genes5–7 and has defined the three types of Pol III genes in humans 
(Fig. 1a), on the basis of (i) the presence and positions of cis regulatory 
elements and (ii) the requirement for particular basal or accessory 
transcription factors. Briefly, 5S rRNA is the sole type 1 gene, uniquely 
requiring TFIIIA. Type 1 and type 2 genes both require TFIIIC, a basal 
factor and targeting complex that recognizes gene-internal A-box and 
B-box elements at type 2 genes but not type 1 genes. The TFIIIB 
complex includes the TATA-binding protein, needed for promoter 
recognition and Pol III initiation. Type 2 and type 3 genes use alter-
native assemblies of TFIIIB:BRF1 for type 2 and BRF2 for type 3 
genes. Type 3 genes lack an internal A or B box and lack reliance on 
TFIIIC, relying instead on upstream proximal and distal sequence 
elements (PSEs and DSEs) and specific factors (OCT1, SNAP and 
others) for targeting. Notably, type 3 Pol III promoters resemble Pol II 
genes in their architecture, which have upstream regulatory elements 
rather than gene-internal elements.
Here we have applied genomics approaches toward the following 
goals: (i) to define human Pol III transcriptomes by occupancy of 
the Pol III machinery, (ii) to discover new or alternative Pol III loci, 
(iii) to classify all Pol III genes by the specialized Pol III machinery 
present and (iv) to provide new insights regarding the placement and 
regulation of Pol III genes in chromosomes and chromatin.
RESULTS
Localization of Pol III in HeLa reveals gene classes
To define Pol III transcriptomes, we applied chromatin immuno-
precipitation (ChIP) of Pol III machinery to determine occupied loci, 
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RNA polymerase (Pol) III transcribes many noncoding RNAs (for example, transfer RNAs) important for translational capacity 
and other functions. We localized Pol III, alternative TFIIIB complexes (BRF1 or BRF2) and TFIIIC in HeLa cells to determine the 
Pol III transcriptome, define gene classes and reveal ‘TFIIIC-only’ sites. Pol III localization in other transformed and primary cell 
lines reveals previously uncharacterized and cell type–specific Pol III loci as well as one microRNA. Notably, only a fraction of 
the in silico–predicted Pol III loci are occupied. Many occupied Pol III genes reside within an annotated Pol II promoter. Outside 
of Pol II promoters, occupied Pol III genes overlap with enhancer-like chromatin and enhancer-binding proteins such as ETS1 
and STAT1. Moreover, Pol III occupancy scales with the levels of nearby Pol II, active chromatin and CpG content. These results 
suggest that active chromatin gates Pol III accessibility to the genome.
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as RNA sequencing cannot determine all active tDNA loci owing to 
the small fraction (21%) of uniquely mappable tDNAs (see Online 
Methods). Thus, Pol III occupancy of the unique flanking region 
(determined by ChIP coupled with massively parallel sequencing 
(ChIP-seq) or ChIP followed by complementary DNA microarray 
hybridization (ChIP-array)) was a proxy measurement of gene acti-
vity. We chose HeLa cells for our initial Pol III transcriptome, and we 
localized RNA Pol III itself (RPC32 subunit) by standard ChIP-array 
approaches, probing the unique portion of the human genome at 
~150–base pair (bp) resolution (Agilent Technologies). A threshold 
of 8.5-fold enrichment yielded 271 sites bound by Pol III and included 
the vast majority of formerly verified unique Pol III genes, a few can-
didate unique loci and approximately half of the predicted tDNAs 
(Supplementary Data 1). With a false discovery rate (FDR) cutoff 
of 1%, ChIP-seq revealed 257 loci bound by Pol III in HeLa cells, 
which overlap 255 annotated Pol III genes and 25 unannotated loci 
(Table 1; full data sets in Supplementary Data 1). Bound loci occa-
sionally encompass closely linked tDNAs (within 600 bp); for Pol III, 
20 bound loci each contain two to four tDNAs. Loci occupied in the 
ChIP-array experiment largely overlapped with those identified by 
ChIP-seq (P < 10−7; Fig. 1b). A small number of Pol III genes reside 
in nonunique regions (5S, small NF90-associated RNA (snaR) genes 
and certain tDNAs; Supplementary Data 1) but are not included in 
the analyses below. In summary, the two genomics formats yielded 
similar Pol III–occupied loci in HeLa cells.
To classify Pol III genes (Fig. 1a), we localized BRF1 (types 1 and 2), 
BRF2 (type 3) and TFIIIC (TFIIIC63 subunit, types 1 and 2, but not type 3) 
by ChIP-seq in HeLa cells. With an FDR cutoff of 1%, we obtained 
242, 16 and 549 occupied loci for BRF1, BRF2 and TFIIIC, respectively. 
Venn diagrams (Fig. 1c), examples (Fig. 1d–f) and class-average maps 
(Fig. 1g–i) reveal two important features. First, BRF1 and BRF2 are 
mutually exclusive, supporting earlier work on individual genes; here 
Type 1: 5S rRNA
TFIIIB
Pol III
TFIIIC TFIIIABDP TBP BRF1
TTTT
A-box IE C-box















































































































































































Figure 1 Occupancy analysis of Pol III and associated machinery in HeLa cells. (a) Pol III–transcribed genes are classified into three types on the basis 
of sequence elements and transcription factors. IE, intermediate element. See Introduction for details. (b) Comparison of Pol III–enriched regions 
obtained by ChIP-array (threshold 8.5-fold over background) and ChIP-seq (FDR < 1%). Most sites appearing unique in the ChIP-array can be explained 
by data thresholding; they are scored as occupied when we lowered the threshold for Pol III in the ChIP-seq format, and they met the high threshold 
(FDR < 1%) in ChIP-seq experiments with other Pol III factors (TFIIIB or TFIIIC). (c) Intersections of Pol III–enriched regions (FDR < 1%) with regions 
enriched by the basal transcription machinery (BRF1, BRF2 and TFIIIC; FDR < 1%). In the Venn diagram, the numbers outside parentheses denote 
known annotated Pol III genes, whereas the numbers within parentheses denote previously uncharacterized Pol III targets. (d–f) Genomic visualization 
of one random example of each of the three types of Pol III genes. The y axis depicts q value FDR (QValFDR) significance values, which correspond to 
P values (50 corresponds to P = 10−5; 100 corresponds to P = 10−10). Values are depicted for Pol III (red), BRF1 (blue), BRF2 (yellow) and TFIIIC63 
(green). The physical map (hg18) is plotted on the x axis. (g–i) Class-average maps of Pol III (red), BRF1 (blue), BRF2 (yellow) and TFIIIC63 (turquoise) 
at type 1 (g), type 2 (h) and type 3 genes (i). The number of read counts at each nucleotide, normalized to the number of genes in the class, is plotted 
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we show this exclusion genome-wide and reveal all separate type 2 and 
type 3 genes in HeLa cells. Second, the majority of TFIIIC-bound loci 
lack Pol III (Fig. 1c), an observation that may be noteworthy given 
the known roles of TFIIIC-only sites in genome organization in lower 
eukaryotes8–11, addressed further below. A compilation of gene types 
and occupancy, including repetitive elements, is provided in Table 1 
and Supplementary Data 1. Notably, we verified the single occupied 
selenocysteine tDNA as the only type 3 tRNA gene in the genome, 
with clear BRF2 occupancy (Supplementary Data 1).
Cell-type variation in Pol III loci
To explore the dynamic and cell type–specific Pol III transcriptome, 
we next performed ChIP-seq of Pol III in three other cell types: human 
embryonic kidney HEK 293T cells (bearing adenovirus and T anti-
gen), human foreskin fibroblasts (HFF; immortalized with human tel-
omerase reverse transcriptase (TERT) but untransformed) and Jurkat 
T cells. For comparison, we intersected the top 400 enriched loci from 
each cell type (Fig. 2a), which overlapped 336, 266, 200 or 168 pre-
dicted Pol III genes in HEK 293T, HeLa, Jurkat and HFF cells, respec-
tively. Notably, 120 genes are clearly occupied in all four cell types. 
In addition, HEK 293T cells have a large number (75; see Fig. 2a) 
of unique loci (primarily tDNAs). Region p22.1 of chromosome 6, 
which harbors the majority of genomic tDNAs, exemplifies cell-type 
 variation (Fig. 2b,c). Of 24 genes showing variance, nine HEK 293T 
genes and one HeLa gene (Supplementary Data 1) met a stringent 
threshold for differential occupancy (>38-fold enriched over back-
ground in HEK 293T or >14-fold in HeLa; enrichment was <3-fold in 
other cell types) in a quantitative PCR (qPCR) format. Thus, although 
the Pol III transcriptomes from these cell types show considerable 
overlap, cell type–specific Pol III–bound loci do exist. In addition, 
we observed that three transformed cell lines share a set of 51 genes 
not occupied in HFF (Fig. 2a).
Occupied tDNAs often reside in Pol II promoters
A particularly noteworthy observation was that only a portion of the 
in silico–predicted tDNAs (ranging from ~30% to ~60%) were occu-
pied by Pol III in the different cell lines (52% in HeLa, Fig. 3a). This 
observation does not derive from data thresholding; rather, percentile 
rank analysis suggests two types of tDNAs, occupied or unoccupied, 
with variation in the occupied class (HeLa, Fig. 3b). This differential 
occupancy is not a mapping artifact, as most tDNAs lacking 
Pol III enrichment can be mapped at >85% efficiency (Supplementary 
Fig. 1). These occupancy differences (occupied compared with 
unoccupied) are also not explained by predicted TFIIIC affinity, as 
Table 1 Pol III genes and Pol III–related repeats in the human genome and enrichment with Pol III initiation machinery in HeLa ChIP-seq
Pol III promoter  
type Class of RNA Subclassa
Number in human 
hg18 reference 
genomeb Number and percentage with attributec
Number and percentage occupied with 
Pol III, BRF1 or BRF2 (FDR < 1%) in 
HeLa
Type 1 5S Consensus 17 17d 100.0% 17e 100.0%
5S-related 1,260 175d 13.9% 0e 0%
Type 2 tRNA Consensus 513 490f 95.5% 242 47.1%
tRNA pseudogeneg 172 120f 69.8% 2 1.2%
tRNA-relatedg 1,224 227f 18.5% 0 0%
Alu Dimerh 1,099,242 638,006f 58.0% 13 0.001%
Monomerh 90,882 30,301f 33.3% 2 0.002%
MIR MIR 587,443 65,530f 11.5% 1 0.0002%
snaR Consensus 21 21f 100.0% 21e 100.0%
snaR-related 7 5f 71.4% 2e 28.5%
HVG or Vault Consensus 3 3f 100.0% 3 100.0%
HVG-related 1 1f 100.0% 0 0%
7SL or SRP Consensus 2 0f 0% 1 50%
7SL-related 954 128f 13.4% 0 0%
BC200 Consensus 1 1f 100.0% 1i 100.0%
BC200-related 253 141f 55.9% 0 0%
Type 3 Y Consensus 4 4j 100.0% 4 100.0%
Y-related 1,123 0j 0% 0 0%
U6 Consensus 9 5j 55.5% 5 55.5%
U6-related 1,670 0j 0% 0 0%
7SK Consensus 1 1j 100.0% 1 100.0%
7SK-related 713 1j 0.1% 0 0%
RNase P Consensus 1 1j 100.0% 1 100.0%
RNase P–related 1 0j 0% 0 0%
RNase MRP Consensus 1 1j 100.0% 1 100.0%
RNase MRP–related 6 0j 0% 0 0%
U6atac Consensus 1 1j 100.0% 1 100.0%
U6atac-related 39 0j 0% 0 0%
tRNASeC Consensus 3k 1f,j 33.3% 1k 33.3%
a‘Consensus’ subclass is based on high sequence identity (using BLAT, http://genome.ucsc.edu) to the validated RNA, except tRNAs, which are compared to the Genomic tRNA Database (http://
gtrnadb.ucsc.edu) and snaRs, which are compared to other studies31. bBased on UCSC Genome Browser (http://genome.ucsc.edu); tracks ‘RNA genes’ and RepeatMasker. (http://www.repeatmasker.
org) (except for tRNAs and snaRs, see footnote a). cAttributes determined with Consensus and Patser programs (http://rsat.ulb.ac.be/rsat; see Online Methods). See Supplementary Data 1 for 
consensus matrices. dContains an internal C-box. eMapped allowing multiple alignments with Bowtie (http://bowtie-bio.sourceforge.net; see Online Methods and Supplementary Data 1). fContains 
an internal B-box. g‘tRNA pseudogene’ from the Genomic tRNA Database; ‘RNA genes’ track; ‘tRNA-related’ subclass consists of all tRNAs in RepeatMasker track (http://genome.ucsc.edu), not 
contained in ‘Consensus’ or ‘tRNA pseudogene’ subclasses. h‘Monomer’ refers to free left or right element (FLAM or FRAM); ‘Dimer’ means the Alu has a FLAM and a FRAM. iEnriched in Pol III 
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MEME12 analysis revealed nearly identical A- and B-box elements at 
occupied and unoccupied tDNAs in HeLa cells (Fig. 3c).
Notably, in HeLa cells, 53 occupied Pol III genes (19%) reside just 
upstream (within 2 kilobases (kb)) of an annotated Pol II gene, a signifi-
cant enrichment in location (P < 10−7). In contrast, only three predicted 
tDNAs within 2 kb of a Pol II gene were unoccupied by Pol III, and two 
of those three tDNAs flank Pol II genes that are inactive in HeLa cells. 
Moreover, histogram plots of all occupied tDNAs residing near Pol II 
genes reveal a pair of peaks at −300 and −900 (Fig. 3d), reflecting the 
relatively common presence of two tandem tDNAs (~600 bp apart) 
just upstream of a Pol II gene. In contrast, tDNAs lacking Pol III do not 
cluster near Pol II genes (Fig. 3d). Finally, adjacent Pol II and Pol III 
genes are often (71%) divergent (see Discussion).
Occupied tDNAs coincide with regions of active chromatin
Intersection analyses revealed Pol III coincident with Pol II protein, 
monomethylated and trimethylated histone H3 Lys4 (H3K4me1 
and H3K4me3), H2A.Z, CTCF and H3.3, at 
levels that were significant (P <10−3) and 
that exceeded our enrichment cutoff of 
ten-fold above random (Supplementary 
Data 2 and ChIP-seq data sets from other studies13–16). Notably, 
the extent of Pol III occupancy scaled with the levels of regional 
Pol II and active chromatin (Fig. 4a–h). To reveal this, we separated 
Pol III–occupied loci into four classes: the top 50, middle 50 and 
bottom 50 occupied loci (remaining above the FDR cutoff of 1%), 
and Pol III–unoccupied tDNAs. We compared occupancy of these 
four classes of loci to levels of Pol II, chromatin modifications 
and chromatin factors (class-average map, centered on the Pol III 
gene transcription start site (TSS)). The levels of Pol II, positive 
histone modifications and H2A.Z all scaled with Pol III occupancy. 
Also, CCCTC-binding factor (CTCF) was observed at a small subset 
(10%) of the tDNAs with the highest Pol III occupancy. In contrast, 
repressive H3K27me3 was more prevalent at predicted tDNAs 
lacking occupancy (below our cutoff) and was not correlated with 
Pol III (Fig. 4f).
The correlations described above would be expected if all tDNAs 






















































































































Figure 2 Differential Pol III occupancy in 
various cell types. (a) Intersection analysis of 
the known Pol III–occupied genes between the 
four cell types. Pol III–bound regions (top 400 
enriched loci) were filtered for unannotated 
regions, and only known genes were used for  
the analysis. Total numbers of genes for HEK 
293T, HeLa, Jurkat and HFF were 336, 266, 
200 and 168, respectively. (b) A depiction 
of chromosome 6 showing Pol III occupancy in 
HeLa (yellow), HEK 293T (blue), Jurkat (red) 
and HFF (green). Bottom, mappable tDNAs.  
(c) Detail of a tDNA cluster in 6p22.1 showing 
Pol III occupancy in the four cell types. Note 
that many tDNAs are differentially enriched with 
Pol III in different cell types.
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Figure 3 Genomic features of Pol III–occupied 
and unoccupied tDNAs in HeLa cells. (a) Venn 
diagram illustrating that predicted tDNAs are 
bound by Pol III or initiation factors (BRF1). 
These 469 tDNAs represent 467 mappable, 
predicted tDNAs plus two Pol III–enriched tRNA 
pseudogenes. (b) All predicted mappable tDNAs 
were ranked by their Pol III occupancy (x axis) 
and plotted against Pol III QValFDR (y axis) to 
show that ~50% of tDNAs are unoccupied by  
Pol III. The dotted line represents the FDR cutoff 
of 1% (QValFDR = 20). (c) Sequence discovery 
(MEME)12 analysis of the regulatory sequence 
elements (A-box and B-box) of tDNAs bound or 
not bound by Pol III. Note that the sequences 
are nearly identical between the two classes 
of tDNAs. (d) Pol III–bound (red) or unbound 
tDNAs (blue) were clustered on the basis of their 
distance from the nearest Pol II gene TSS in  
100-bp bins. Note that Pol III–bound tDNAs 
cluster within 1 kb of the Pol II gene TSS  
(P < 10−7), whereas the unbound tDNAs show  
no such clustering. A tDNA was classified as  
Pol III bound if it was occupied by RPC32,  
BRF1 or both. A promoter was defined as being 
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most tDNAs occupied by Pol III actually reside outside annotated 
Pol II gene promoters (201, or 82%, in HeLa cells). Therefore, we 
separated occupied Pol III genes into two classes—those within anno-
tated Pol II promoters, and those outside—and again examined how 
Pol III occupancy scaled with Pol II and chromatin attributes. Notably, 
active tDNAs outside annotated Pol II promoters still strongly cor-
related with adjacent Pol II and chromatin modifications typical of a 
Pol II promoter or enhancer (including H3K4me1; Supplementary 
Fig. 2 and Supplementary Data 2). In contrast, unoccupied tDNAs 
lack adjacent Pol II or active chromatin (Fig. 4d–h), and instead bear 
higher levels of H3K27me3 (Fig. 4f). An example of this partitioning 
is shown in Figure 4i, where the two Pol III–occupied genes encod-
ing tRNATyrGTA genes also bear Pol II and active chromatin, whereas 
the single Pol III–unoccupied gene encoding tRNATyrGTA lacks these 
factors or attributes. Thus, active tDNAs outside of annotated Pol II 
promoters are found in a chromatin region that resembles an active 
Pol II gene promoter or enhancer. We note that type 3 genes (BRF2-
containing) show active chromatin profiles similar to those of 
type 2 genes.
We found that a considerable fraction (~30%) of Pol III–occupied 
loci reside within CpG islands—a highly significant overlap 
(P < 10−6)—and that a striking correlation exists between Pol III 
occupancy and CpG content at Pol II promoters. Others have sepa-
rated promoters into three types on the basis of their CpG density17: 
high-CpG promoters (HCPs), intermediate-CpG promoters (ICPs) 
and low-CpG promoters (LCPs). Notably, Pol III–occupied promot-
ers intersect well with HCPs (typically associated with constitutively 
active genes) and moderately with ICPs, and are anticorrelated with 
LCPs (Supplementary Data 2). Together with the results above, this 
indicates that Pol III occupancy is enabled by active Pol II promoter–
like chromatin.
Jurkat and HeLa cells show similar Pol III chromatin
Genome-wide chromatin maps in HeLa and primary CD4+ T cells 
are extensive, whereas those in Jurkat, HFF and HEK 293T cells are 
lacking. Jurkat T cells are similar to CD4+ T cells (Jurkat is also a 
CD4+ T cell18), though proliferative and (in our hands) technically 
more amenable to Pol III occupancy analysis. ChIP-seq of Pol III in 
Jurkat cells yielded 211 occupied loci (FDR < 10%), which overlap 
182 annotated genes. This list had high overlap (88%) with the list 
from HeLa cells and showed similar trends; Pol III–occupied loci 
were correlated with (and scaled with) Pol II and active Pol II pro-
moter-like chromatin (Fig. 5a, Supplementary Figs. 3 and 4, and 
chromatin ChIP-seq data sets from other studies19–22), and anti-
correlated with additional repressing modifications (for example, 
H3K36me3; Supplementary Data 2). However, with resting CD4+  
T cells, the correlations of Pol III with adjacent Pol II were weaker, and 
correlations of Pol III with adjacent H2A.Z were stronger, possibly 
reflecting the ‘poised’ nature of many genes in resting CD4+ cells. 





























































































































































Figure 4 Chromatin features at Pol III–bound tDNAs in HeLa cells. (a–h) We binned Pol III–bound genes into three categories—top 50 (blue), middle 
50 (red) and bottom 50 (yellow)—on the basis of their Pol III levels, and plotted class-average maps for various factors and chromatin marks13–16. 
Class-average plots of factors at tDNAs without Pol III (turquoise) serve as negative controls. The distance from the Pol III TSS is plotted on the  
x axis, and the number of read counts at each nucleotide, normalized to the number of regions in the class, is plotted on the y axis. The fraction of 
each of these factor-bound regions intersecting with the top-50 class is indicated in blue at top right corner of each graph. (i) Example of a genomic 
locus showing a tDNA cluster with differential occupancy of Pol III, BRF1, TFIIIC63, H3K4me3 and Pol II. Note that the tRNATyr gene lacking Pol III 
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adjacent to tDNAs when CD4+ T cells are activated (Supplementary 
Data 2, and Pol II and H2AZ data from other studies23).
Occupied Pol III loci correlate with STAT1 and ETS1
Our results prompt two questions regarding the establishment of 
Pol III–correlated chromatin: (i) whether there are specific DNA 
binding factors or activators that colocalize with Pol III–occupied 
regions, and (ii) whether the unannotated loci bearing Pol III and 
Pol II might represent enhancers or enhancer-like regions. We com-
pared our data sets to the extensive transcription factor binding pro-
files in T cells (Jurkat and CD4+)—except for STAT1, for which binding 
profiles13,24 in HeLa were directly compared. Certain transcription fac-
tors have been linked to Pol III regulation (p53, c-MYC and RB)25,26, 
but the lack of genome-wide ChIP-seq data sets prevented us from 
comparing their binding profiles with our data. However, we found a 
notable overlap between Pol III occupancy and the general transcrip-
tion factors STAT1 (ref. 13) (in HeLa, FDR < 1%, overlap 161 of 278 
loci, P < 10−5) and ETS1 (ref. 22) (in Jurkat, overlap 144 of 182 loci, 
P < 10−5; Fig. 5b). Moreover, using the list of STAT1-occupied sites 
generated in ref. 24 (FDR < 0.1%), we derived an overlap of 254 of 
278 loci. Notably, STAT1 binding sites reside very near the Pol III 
gene TSS, for Pol III genes both within and outside of annotated 
Pol II gene promoters (Fig. 5c and Supplementary Fig. 4f). ETS1 has 
different properties at promoters compared with enhancers22. For 
example, sites within Pol II promoters are typically consensus sites, 
and a feature of promoter-localized ETS1 is that it lacks precise co-
alignment with CREB-binding protein (CBP) occupancy. In contrast, 
ETS1 sites at enhancers show considerable variation from consensus, 
and they often physically partner with other transcription factors 
(for example, RUNX1). Also, ETS1 at enhancers is aligned more pre-
cisely with CBP occupancy22. In keeping with these different properties 
at promoters and enhancers, we found that Pol III–occupied anno-
tated promoters bearing ETS1 are typically consensus sites (data not 
shown) and lack precise alignment with CBP (Fig. 5d). In contrast, the 
tDNAs not adjacent to annotated Pol II genes coincide with enhancer-
like ETS1 sites (data not shown) that are well aligned with CBP 
(Fig. 5e). This raises the possibility that particular enhancer-binding 
proteins such as STAT1 and ETS1 help nucleate open chromatin at 
promoters or enhancers, which then promotes Pol III occupancy (see 
Discussion). We also saw marked overlap with the transcription factor 
SRF (FDR < 1%, 52 of 182 loci) and moderate overlap with GABP 
(FDR < 1%, 29 of 182 loci). However, we observed little overlap with 
NRSF (FDR < 1%, 10 of 182 loci) in Jurkat cells (Supplementary 
Fig. 4g–i and data from other studies21).
Enhancers strongly correlate with three chromatin attributes27—
H3K4me1, acetylation of H3K27 (H3K27ac) and DNase I hyper-
sensitivity—for which maps are available in CD4+ T cells or HeLa 
cells. We saw highly significant overlap between Pol III occupancy at 
unannotated regions and the presence of H3K4me1 (P < 10−5) and 
H3K27ac (P < 10−5) (Supplementary Data 2 and Supplementary 
Fig. 3b,i,r). Furthermore, of the 150 occupied tDNAs in Jurkat cells, 
145 overlap DNase I–hypersensitive sites (P < 10−5), whereas only 
96 of the 321 unoccupied tDNAs do. Notably, 59 of those hypersensitive 
sites become enriched with Pol III in HeLa cells.
Occupied tDNAs correlate with enhancer-like chromatin, which 
typically does not produce RNA. However, the presence of Pol II at 
these loci prompted us to address whether transcription by Pol II 
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Figure 5 Chromatin marks and factors 
associated with Pol III–bound regions in 
Jurkat cells. (a) Example of a genomic  
locus showing a tDNA bound by Pol III  
(red) in Jurkat cells. Also shown are active 
acetylation (purple) and methylation (green) 
marks, H2A.Z (blue), Pol II (turquoise) and 
transcription factors (yellow). This putative 
enhancer is ~12 kb upstream of a Pol II gene 
TSS. Chromatin and factor ChIP-seq are  
from other studies19–22. (b) Intersection of  
Pol III–bound regions (FDR < 10%) with 
regions bound by ETS1 (FDR < 1%; filtered  
for regions overlapping DNase I hypersensitivity 
in CD4+ cells41) and CBP (FDR < 1%) in 
Jurkat cells. (c) Pol III–bound genes in HeLa 
(FDR < 1%) were binned into those inside 
(red) or outside (blue) annotated Refseq 
promoters, and a class-average map of STAT1 
was plotted; tDNAs without Pol III (turquoise) 
serve as a negative control. The numbers 
denote the fraction of total Pol III genes 
occupied by STAT1 for loci either inside  
(red) or outside (blue) Refseq promoters.  
(d,e) Class-average maps of ETS1 (red)  
and CBP (blue) at Pol III–bound genes  
inside (d) or outside (e) Refseq promoters 
in Jurkat cells. The red and blue dashed 
lines indicate approximate peaks of the 
corresponding factors. The fractions of  
Pol III regions intersecting with ETS1  
(FDR < 1%) and CBP (FDR < 1%) in  
Jurkat are indicated in red and blue, 
respectively. (f) Average score of HeLa RNA-seq read per kb for each 1-kb region flanking tDNAs. Error bars represent s.e.m. Note that transcripts 
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(RNA-seq) of total RNA in HeLa and quantified reads in the 
region flanking the tDNAs. This region contains the peak of Pol II 
(Supplementary Fig. 2d) but not the tDNA itself (or Pol III), so that 
reads from only Pol II were compiled. At these tDNAs in enhancer-
like chromatin, we did not generally observe RNA transcripts in the 
aforementioned region (Fig. 5f). This suggests that ‘active’ chro-
matin modifications, including those involved in Pol II initiation 
(for example, H3K4me3), but not Pol II transcripts per se, best 
 correlate with Pol III occupancy.
Previously uncharacterized Pol III genes and miRNAs
ChIP-seq data yielded 42 candidates for previously uncharacterized 
Pol III loci in HeLa cells. From these, we tested 13 by qPCR; ten were 
enriched at least 3.5-fold above background for Pol III occupancy. One 
noteworthy unannotated locus is about 2 kb upstream of the SLC7A2 
TSS, which shows nearby STAT1, H3K4me3, Pol II and a transcript by 
RNA-seq (Supplementary Fig. 5a–c). Another candidate locus resides 
on chromosome 5 among multiple repeats. Here, BRF2 and Pol III 
colocalized over an L1M5 long interspersed nuclear element (LINE), 
with STAT1, Pol II and H3K4me3 nearby (Supplementary Fig. 5d–f). 
This could represent a previously uncharacterized type 3 gene; there 
are only 14 type 3 genes currently known. We also identified one 
MIR highly enriched with Pol III, BRF1 and TFIIIC in the first intron 
of POLR3E (Supplementary Fig. 5g,h). These positives, in addition, 
include other loci in promoters of Pol II–transcribed genes, such as 
ADARB1, FZR1 and the U1 small nuclear RNA gene, or near other 
retroviral elements (for example, MER41C LTR) (Supplementary 
Fig. 6a,b). Furthermore, we found six annotated tRNA pseudogenes 
enriched at high levels in various cell types, and we verified two by 
qPCR (Supplementary Fig. 6c and Supplementary Data 1). Finally, 
we also found 17 Pol III genes within Pol II transcriptional units 
(mostly in introns; data not shown).
For repetitive regions, we applied mapping algorithms that allow 
multiple alignments (Bowtie; http://bowtie-bio.sourceforge.net), 
which revealed Pol III enrichment (and often enrichment of other 
Pol III factors; see Supplementary Data 1) at snaR-class genes, at all 
of the consensus 5S rDNA genes on chromosome 1 (but no other 
5S-related genes), at multiple Alu elements and at 35 tDNAs that 
map inefficiently. However, the human papillomavirus 18 and 45S 
rDNA loci were not occupied.
Pol III has been reported to transcribe multiple miRNAs on the 
chromosome 19 miRNA cluster (C19MC)28, driven by Alu promo-
ters in HEK 293T cells, which would represent the first example, to 
our knowledge, of Pol III–driven miRNAs. However, after remapping 
our reads for HeLa, HEK 293T and HFF, allowing multiple align-
ments, we saw no enrichment of Pol III at any region (or miRNA) in 
this highly repetitive cluster (data not shown), a negative result sup-
ported by recent evidence showing transcription of C19MC by Pol II 
instead29. Another study30 supports two additional Pol III–transcribed 
loci, SNAR-A (ref. 31; also known as CBL-1) and MIR886 (ref. 32; also 
known as CBL-3), but the authors did not test for occupancy by Pol III. 
Here we show clear occupancy of both loci (Supplementary Fig. 7); 
we also observed transcripts lacking a 5? cap derived from the MIR886 
locus by RNA-seq (see Online Methods and Supplementary Fig. 7d). 
To our knowledge, this is the first direct evidence for occupancy and 
transcription by the Pol III machinery of a miRNA in mammals.
TFIIIC-only and TFIIIB-TFIIIC sites
Given the role in yeast chromatin organization of loci bound by TFIIIC 
but not Pol III, BRF1 or BRF2 (refs. 8–11), we identified 307 such loci 
in HeLa cells. TFIIIC-only sites partition into two classes: loci adjacent 
to Alu or MIR repeats, or both (181), and those that lack repeats (126). 
Certain loci were adjacent to both an MIR and an Alu element, which 
accounts for the higher number of total TFIIIC-only loci (377) depicted 
in Figure 1c. Notably, 101 TFIIIC-only loci reside within 2 kb of the 
TSS of an annotated Pol II gene, 60% of which have HCP Pol II pro-
moters, a highly significant enrichment (P < 10−5), whereas 206 reside 
in unannotated regions (Supplementary Fig. 8a). Those within anno-
tated Pol II genes show correlations with active promoter chromatin 
(Supplementary Fig. 8b–i and Supplementary Data 2). Those in unan-
notated regions also show strong correlations with active chromatin, 
though weaker than with annotated Pol II genes (Supplementary Data 2). 
Notably, TFIIIC-only sites near Alu and MIR elements typically have a 
B-box (164 of 181) and bear high levels of H3K4me1, H3K4me3 and 
Pol II, whereas those distal from repeats are generally void of positive marks 
and typically lack a consensus B-box element (27 of 126 have a B-box) 
(Supplementary Fig. 8b–i), raising the possibility that TFIIIC cooperates 
with other factors for binding at these loci. MEME12 and TOMTOM33 
analysis revealed the consistent presence of a G/A-rich site with signifi-
cant (P = 0.00028) similarity to the binding site of Kruppel-like factor 4 
(KLF4; Supplementary Fig. 8j). Nineteen sites in our HeLa data sets 
contain both TFIIIB (BRF1) and TFIIIC, but lack Pol III enrichment 
(at our threshold of FDR < 1%). However, the majority (14 of 19) 
of these sites become enriched with Pol III in HEK 293T cells, or in 
HeLa cells if compared with a lower threshold (FDR < 5%, Pol III 
ChIP-seq) or our Pol III ChIP-array data set (data not shown). At 
present, it is not clear whether these sites are truly different in their 
mode of Pol III recruitment or they simply represent sites near our 
occupancy cutoff thresholds.
DISCUSSION
Our data sets and analyses address the scope and regulation of human 
RNA Pol III transcriptomes, providing multiple insights (Fig. 6). First, 
we observed the close proximity of Pol III genes to Pol II genes genome-
wide. This result is in keeping with previous work at the Pol III– 
transcribed U6 small nuclear RNA gene (a type 3 gene), which has a 
proximal Pol II that assists in Pol III expression34. Second, we show 
genome-wide a marked overlap of Pol III with active chromatin. 
Previous work at U6 supports the notion that nearby chromatin 
remodeling promotes U6 expression35, and our work extends this 
concept genome-wide to all type 2 and type 3 genes, and also to many 
active histone modifications and compositions. Notably, ~81% of 
occupied Pol III genes reside at regions outside of annotated Pol II 
genes, yet those regions bear high levels of H3K4me3 and Pol II 
protein, properties typical of promoters. Notably, these unanno-
tated regions also have properties of enhancers27, as they contain 
H3K4me1 and H3K27ac, and overlap with enhancer-binding proteins 
and DNase I–hypersensitive sites. In addition, we found few, if any, 
transcripts adjacent to most of these unannotated Pol II peaks, and 
those we found generally lack a long downstream open reading frame. 
Thus, it is not entirely clear whether one should consider these regions 
new unannotated promoters or instead a subclass of enhancers that 
contain Pol II and H3K4me3, resembling Pol II ‘poised’ promoters. We 
speculate that the promoter-like chromatin formed near either ‘poised’ 
or active Pol II might be sufficient for enabling Pol III occupancy. In 
addition, it will be of interest to determine whether these unannotated 
promoters or enhancers produce a functional transcript in particular 
cell types, or whether they are typical enhancers, activating 
another Pol II gene in the larger region. Regardless, the overlap of 
Pol III–occupied tDNAs with active chromatin is striking. Notably, Pol III 
occupancy scaled with active chromatin marks and proximal Pol II, 
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connection of Pol III occupancy with active chromatin. Finally, DNA 
hypomethylation may also contribute to the active chromatin state, 
as occupied Pol III genes correlated with regions having high CpG 
content (which are typically unmethylated) and as STAT1 consensus 
sites are strongly correlated with DNA hypomethylation36.
Occupied Pol III genes often reside 300–900 bp upstream of the 
Pol II TSS—close enough to overlap with promoter-proximal chro-
matin, but generally not within the promoter-proximal region where 
the Pol II basal machinery assembles. Furthermore, tDNAs residing 
in Pol II promoters are typically transcribed away from the Pol II 
gene (divergent orientation), with a significant bias (P = 0.006). We 
suggest that these properties allow the Pol III gene to benefit from 
promoter chromatin dynamics while avoiding interference with the 
transcription of the Pol II gene itself. Previous Pol III transcriptomes 
in Saccharomyces cerevisiae10,37,38 have shown that virtually all pre-
dicted Pol III genes (including tDNAs) are occupied by Pol III, pro-
viding evidence against appreciable Pol III regulation by chromatin 
or position relative to Pol II genes. Moreover, S. cerevisiae lacks key 
modifications of vertebrate heterochromatin (H3K9me3, H3K27me3 
and DNA methylation), suggesting that Pol III in human cells may 
encounter chromatin obstacles not present in lower yeasts.
Our work also reveals moderate variation in Pol III occupancy 
among cell types, and cell type–‘specific’ occupancy of a small number 
of loci. Here specificity is defined using a stringent criterion, but very 
low occupancy of these ‘specific’ loci may exist in other cell types. A key 
issue is the basis for cell-type variation and specificity. One possibility 
is that as each cell type varies its repertoire of Pol II gene transcrip-
tion and active enhancers, the Pol III genes that overlap the permis-
sive chromatin gain access to the Pol III machinery. According to this 
model, Pol III relies on both general Pol II transcription factors and 
cell type–specific factors to create open or active chromatin. Although 
active chromatin may gate Pol III access, it does not constitute all of 
Pol III regulation: the activity of occupied Pol III genes is probably still 
regulated by other factors such as the general Pol III repressor MAF1 
(ref. 39). Furthermore, we emphasize that although these models are 
based on extensive sets of strong correlations, genetic experiments are 
required to determine their dependency relationships.
Notably, tDNAs are thought to have expanded in the genome via 
retrotransposition40, and retrotransposons often insert in regions of 
open chromatin. One interpretation of our data is that the juxtapo-
sition of active Pol III genes (~300) with active Pol II chromatin is 
largely a consequence of this initial accessibility during transposition, 
which would imply that these regions were accessible in the germline at 
some point during evolution. However, there are an additional ~1,396 
tRNA-derived elements in the genome, and these are generally not 
occupied by Pol III machinery (~0.1% occupied). Furthermore, as a 
class these elements are not coincident with active chromatin (data not 
shown), raising the possibility that transposition may have occurred in 
the germline and placed these elementsinto inactive chromatin, with 
inactive chromatin preventing their subsequent expression and contri-
bution to fitness, allowing sequence drift. Alternatively, it may be that 
the transposition placed them into active chromatin, but these regions 
were later converted into heterochromatin, with similar consequences. 
Regardless, we observed active chromatin coincident with active Pol III 
genes and not with tRNA-derived elements.
In addition, our work reveals many new Pol III–occupied loci 
in multiple cell types, and these loci also require functional work 
in vivo. For the three new loci clearly enriched with Pol III machin-
ery (Supplementary Fig. 5), we propose names that include a ‘P3’ 
(Pol III) designation: for the MIR in the POLR3E intron, MIRP3; for 
the chromosome 8 locus conserved in primates, CPP3; for the LINE 
L1M5 locus, L1M5P3. Furthermore, we reveal the transcription of a 
miRNA, clarifying and extending earlier work30,32. It will be of inter-
est to identify the Pol III transcriptomes of pluripotent cell lines or 
early embryos to determine whether additional noncoding RNAs are 
produced by Pol III.
METHODS
Methods and any associated references are available in the online 
version of the paper at http://www.nature.com/nsmb/.
Accession codes. Gene Expression Omnibus: GSE20309 (all ChIP-seq 
data) and GSE20609 (Pol III ChIP-array data).
Note: Supplementary information is available on the Nature Structural & Molecular 
Biology website.
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ONLINE METHODS
Cell culture and cross-linking. We used cross-linked HeLa S3 cells (Biovest 
International) for ChIP-array and most HeLa ChIP-seq. For a second replicate 
of RPC32 ChIP, we obtained HeLa cells from ATCC (Cat. CCL-2.2) and cultured 
them in DMEM, 10% (v/v) FBS and 10 mM glutamine. We harvested cells at 
~80% confluence and cross-linked them in 1% (v/v) formaldehyde for 30 min. 
We cultured and cross-linked Jurkat, HEK 293T and HFF (with TERT) cells as 
for HeLa (except we grew Jurkat cells in RPMI). We obtained Jurkat E6-1 cells 
from ATCC (Cat. TIB-152).
Chromatin immunoprecipitation. We used Standard Agilent Technologies 
Mammalian ChIP-on-chip protocol version 10.0 (http://www.agilent.com) for 
ChIP-array. For ChIP-seq, we made the following modifications. We lysed nuclei 
in 50 mM Tris-HCl, pH 8, 100 mM NaCl, 10 mM EDTA and 1% (w/v) SDS. We 
sheared chromatin by sonicating (Misonix) 10–20 times on setting 4–5 to an 
average shear length of 200–400 bp. For each immunoprecipitation, we bound 
100 ?l Dynabeads (Invitrogen) to 5–10 ?g antibody in dilution buffer (15 mM Tris, 
pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% (w/v) Triton X-100, 2 mg ml−1 BSA) for 
5 h to overnight (16 h). We precleared chromatin sonicate from 20–40 × 106 cells in 
1.4 ml dilution buffer with 50 ?l Dynabeads for 1 h and transferred it to bead–
antibody complexes for overnight immunoprecipitation. We washed and eluted 
the immunoprecipitate and reversed cross-links in 200 mM NaCl as described42. 
We purified DNA from eluate with phenol-chloroform-isoamyl (25:24:1, pH 8; 
Invitrogen) and Qiagen PCR Purification. We used these antibodies for immuno-
precipitation: anti-RPC32 (Santa Cruz Biotechnologies, sc-21754), anti-RPB90 
(that is, anti-BRF1), anti-BRF2 (abcam, ab17011) and anti-TFIIIC63 (Bethyl 
Laboratories, A301-242A).
ChIP-array. We designed ten ~1-million-feature custom microarrays tiling the 
nonrepetitive human genome (average resolution of 150 bp) from the Agilent 
ChIP database. We carried out RPC32 ChIP eluate amplification, labeling, 
array hybridization and wash according to Agilent Mammalian ChIP-on-chip 
protocol version 10.0. We scanned arrays with Agilent Technologies’ Scanner C 
(cat. G2505C) and performed feature extraction with Agilent Technologies FE 
version 10.1.1.22 using default ChIP settings. We analyzed arrays using DNA 
Analytics’ ChIP-chip analysis module (Agilent) and determined bound regions 
using default settings.
RNA-seq. We seeded 107 HeLa S3 cells per plate on two 15-cm dishes overnight. 
We washed cells with warm PBS, added 5 ml Trizol (Invitrogen) per plate and 
purified total RNA. We subjected RNA to RiboMinus (Invitrogen) or double 
7-methylguanosine cap purification43 plus RiboMinus before preparing RNA-
seq libraries.
Sequencing. We used the Illumina GA2 with standard protocols for preparing and 
sequencing libraries. Read numbers are unique satellite-filtered reads (26–36 bp): 
input HeLa, 20,691,965; RPC32 HeLa, 13,082,194; BRF1 HeLa, 10,986,064; BRF2 
HeLa, 11,053,174; TFIIIC HeLa, 16,076,219; RPC32 Jurkat, 18,173,688; RPC32 
HFF, 8,917,992; RPC32 HEK 293T, 7,762,672; total RNA HeLa, 4,392,375; capped 
RNA HeLa, 5,934,673. When multiple alignments were desired, we remapped 
reads with Bowtie (http://bowtie-bio.sourceforge.net), retaining either the 
top 5 or the top 15 alignments.
Analysis of ChIP-seq data. We analyzed ChIP-seq data with the USeq package 
(http://useq.sourceforge.net). We used Jurkat input reads21,22 to analyze RPC32 
ChIP data from Jurkat, HFF and HEK 293T, as well as ChIP-seq tags for CD4+ 
and Jurkat from other studies19–23,44, unless provided. We used HeLa input reads 
from this study to analyze all HeLa data sets produced in this study, as well as 
HeLa ChIP-seq tags from other studies13–16, unless provided. We created the 
‘random regions’ file for IntersectRegions by pooling data from this study and 
others13,14,19,20,22 and merging all 110-bp windows with at least one read; this 
is an estimate of the uniquely mappable genome. We removed duplicate align-
ments of RPC32 HeLa replicate 2, HEK 293T and HFF data sets. We performed 
Venn intersections using a Perl script (available upon request). We determined 
mapping efficiency of a tDNA by tiling every possible 36-bp sequence within 
the tDNA (plus 100 bp upstream and downstream sequence for ChIP-seq). The 
expected number of mappable reads for 100% efficiency is the number of tiles. 
We aligned the tiles uniquely with Bowtie (http://bowtie-bio.sourceforge.net) and 
calculated percent of observed mapped tiles over expected. We used only tDNAs 
overlapping the ‘random regions’ file for analysis. See Supplementary Data 1 for 
lists and further descriptions. We used the Integrated Genome Browser (IGB, 
http://igb.bioviz.org/) for screen shots.
Consensus binding sites. We used Consensus and Patser (http://rsat.ulb.ac.be/
rsat) to determine position-weight matrices for consensuses in Table 1 from 
Pol III–enriched genes, and to search for the consensus in repeats. We down-
loaded sequences for repeats in Table 1 from UCSC (http://genome.ucsc.edu) 
tracks RepeatMasker (http://www.repeatmasker.org) and ‘RNA genes’, except that 
tDNAs were from the Genomic tRNA Database (http://gtrnadb.ucsc.edu). We 
analyzed A- and B-boxes of tDNAs as well as TFIIIC-only and KLF4 consensuses 
with MEME and TOMTOM (http://meme.sdsc.edu).
Real-time PCR. For qPCR reactions, we used 1:50 to 1:100 of ChIP eluate, 
500 nM primer, and iQ SYBR Green Supermix (Bio-Rad) in a total volume of 
20 ?l. We serially diluted ChIP input DNA for a standard curve. We designed 
primers of annealing temperature 62–65 °C with a single melt curve peak 
(Supplementary Table 1). We analyzed PCR results with iCycler (Bio-Rad).
Statistical analysis. Others have detailed a full description of statistical meth-
ods used in USeq programs45. To generate P values and fold enrichment over 
random in intersections of data sets, as well as to determine statistical signif-
icance of the positions of Pol III genes with respect to Pol II Refseq TSS, we 
used IntersectRegions (USeq package), which uses multiple permutation tests 
of random regions, as described46. We generated the P value for the divergent 
orientation of Pol II and nearest Pol III gene with the binomial P value function 
in R (http://www.r-project.org).
Data availability. The processed data is available for programmatic access using 
the GenoPub DAS/2 data distribution server (description, http://bioserver.hci.
utah.edu/BioInfo/index.php; software, DAS2, GenoPub web app, http://bioserver.
hci.utah.edu:8080/DAS2DB/genopub, and the DAS/2 data access URL, http://
bioserver.hci.utah.edu:8080/DAS2DB/genome). One can use DAS/2-compliant 
genome browsers such as the Integrated Genome Browser (http://igb.bioviz.org/) 
to view the data sets, found under Homo sapiens?H_sapiens_Mar_2006?
Cairns Lab?Oler_2010.
42. Gordon, M. et al. Genome-wide dynamics of SAPHIRE, an essential complex for 
gene activation and chromatin boundaries. Mol. Cell. Biol. 27, 4058–4069 
(2007).
43. Choi, Y.H. & Hagedorn, C.H. Purifying mRNAs with a high-affinity eIF4E mutant 
identifies the short 3? poly(A) end phenotype. Proc. Natl. Acad. Sci. USA 100, 
7033–7038 (2003).
44. Schones, D.E. et al. Dynamic regulation of nucleosome positioning in the human 
genome. Cell 132, 887–898 (2008).
45. Nix, D.A., Courdy, S.J. & Boucher, K.M. Empirical methods for controlling false 
positives and estimating confidence in ChIP-Seq peaks. BMC Bioinformatics 9, 523 
(2008).
46. Hammoud, S.S. et al. Distinctive chromatin in human sperm packages genes for 
































Supplementary Figure 1 Highly mappable tDNAs can be bound or unbound by Pol III.  tDNA 
sequences are non-unique and lack of Pol III occupancy at a certain tDNA could be either 
because it is not occupied or because it is not uniquely mappable. To distinguish between 
these possibilities, each of 513 predicted tDNAs is assigned a mapping efficiency rank (x-axis) 
based on how efficiently a tDNA can be mapped (see Methods for a description of determining 
mapping efficiency). A tDNA with a lower rank number is more uniquely mappable than a tDNA 
with a higher rank number. The plot shows the QValFDR of Pol III in HeLa (primary y-axis) for 
each of the ranked tDNAs. Highly mappable tDNAs can be bound (QValFDR>20, above dotted 
line) or unbound (red points with QValFDR between 0–20). Primary y-axis is split to enlarge 
the region from QValFDR 0–20.  The secondary y-axis shows the mapping efficiency of the 
tDNA with 100bp flanking sequence (see Methods). Of a total of 513 predicted tDNAs, ~467 
are mappable (at rank ~467, the mapping efficiency curve falls steeply from 80% to 0% 
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Supplementary Figure 2 HeLa-Pol III bound genes inside and outside Pol II promoters 
correlate with active chromatin. Pol III bound genes in HeLa (FDR<1%) were binned into those 
either inside (red) or outside (blue) Refseq promoters, and class average maps of chromatin 
marks and factors at these two classes of Pol III bound genes were plotted.  The x-axis is the 
distance in base pairs from the Pol III transcription start site (TSS).  An average Pol III gene is 
depicted as being transcribed rightward, with zero being the TSS, negative numbers indicating 
upstream regions and positive numbers indicating downstream regions. The y-axis is the 
number of read counts at each position normalized to the number of genes in the class. The 
numbers in red and blue indicate the intersection fractions for marks/factor-enriched regions 
with Pol III bound regions inside and outside Refseq promoters, respectively. Chromatin 
datasets from others1–4. 
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Supplementary Figure 3 Active chromatin marks at Pol III bound genes in Jurkat cells scale 
with Pol III occupancy. Pol III bound genes in Jurkat cells were binned into Top 50 (blue), 
Middle 50 (red) and Bottom 50 (yellow) based on their Pol III levels and class average maps 
were plotted for various marks/factors. Class average plots of marks/factors at tDNAs without 
Pol III (green) serve as negative controls. The x-axis is the distance from the Pol III TSS and 
the y-axis is the number of read counts at each position normalized to the number of regions in 
the class. The intersection fraction for each of these factor bound regions with the Top 50 class 
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Supplementary Figure 4 Transcription factors at Pol III bound genes in Jurkat cells scale with 
Pol III occupancy. Pol III bound genes in Jurkat cells were binned into Top 50 (blue), Middle 50 
(red) and Bottom 50 (yellow) based on their Pol III levels and class average maps were plotted 
for various marks/factors. Class average plots of factors at tDNAs without Pol III (green) serve 
as negative controls. The x-axis is the distance from the Pol III TSS and the y-axis is the 
number of read counts at each position normalized to the number of regions in the class. The 
intersection fraction for each of these factor bound regions with the Top 50 class is indicated in 
blue.  Chromatin and factor ChIP-seq from others2,5–8. 
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Supplementary Figure 5 Quantitative PCR confirms novel Pol III targets identified by ChIP-
seq. (a,d,g) Novel Pol III (red), Pol II (turquoise), H3K4me3 (light green), and STAT1 (orange) 
bound regions. (Pol II, H3K4me3, STAT1 datasets from others1,2.) (a) Novel locus on 
chromosome 8, CPP3, in SLC7A2 promoter with Pol III (red), BRF1 (blue), STAT1 (orange), 
and H3K4me3 (light green) nearby.  The Pol III ChIP-chip track (dark green) shows the 
variably enriched (based on color intensity) tiles as assayed by ChIP-array, peaking at 34.8-
fold enrichment over background.  ESTs (yellow) have been mapped to the reverse strand with 
the longest EST terminating 128bp downstream of the start at a stretch of five Ts, a typical 
terminator for Pol III.  We also observe a B-box (asterix) at +57 from the putative TSS and the 
putative transcript is predicted to fold into a structure similar to snaR-B RNA (data not shown).  
Note that the total RNA track (purple) shows a transcript made at this locus in HeLa cells. (b,c) 
Quantitative PCR (qPCR) analysis of (b) Pol III or (c) BRF1 ChIP eluate in HeLa cells showing 
occupancy at the novel Pol III bound region as shown by ChIP-seq. Green bars indicate 
positive controls that are known Pol III targets, blue bars negative controls and red bars novel 
targets.  Error bars represent standard error of the mean (s.e.m.) of three replicates.   y-axis 
represents relative starting template copy number based on standard curve of genomic DNA. 
(d) Novel Pol III (red), BRF2 (yellow), Pol II (turquoise) and H3K4me3 (light green) bound 
region overlapping L1M5 LINE fragment; putative Pol III gene called L1M5P3.  (e,f) qPCR 
analysis of (e) Pol III or (f) BRF2 ChIP showing enrichment at L1M5P3 as seen in ChIP-seq.  
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qPCR results graphed as in b,c.  Gene encoding RNase P RNA, RPPH1, is a positive control.  
(g) Novel Pol III (red), BRF1 (blue), TFIIIC (dark green), H3K4me3 (light green), Pol2 
(turquoise) and STAT1 (orange) bound mammalian-wide interspersed repeat (MIR) in the 
intron of POLR3E; novel Pol III gene called MIRP3.  This region also shows RNA transcripts 
(pink). (h) Tiling ChIP-qPCR analysis of Pol III genes near TSS of POLR3E shows that Pol III 
is enriched at two separate loci flanking the annotated Pol II TSS: tRNALeu-AAG upstream 
and MIR in the first intron.  qPCR results graphed as in b,c.  See g for location of amplicons 
A–D on physical map. 
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Supplementary Figure 6 Novel unannotated regions bound by Pol III in HeLa cells. (a–c) 
ChIP-qPCR analysis of some novel Pol III-bound sites from ChIP-seq analysis show >3.5-fold 
enrichment over a negative control locus.  Green bars indicate positive controls that are known 
Pol III targets, blue bars are negative controls, and red bars are novel Pol III bound regions.  
Error bars represent s.e.m. of three replicates.  y-axis represents relative starting template 
copy number based on standard curve of genomic DNA. In c, a single 5S gene bears a point 
mutation that allows us to query Pol III enrichment at this gene.  See Supplementary Table 1 
for primer sequences. 
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Supplementary Figure 7 Novel demonstration of Pol III machinery binding to SNAR-A and 
MIR886 in HeLa cells. (a) ChIP-seq reads mapped to permit multiple alignments allows us to 
visualize enrichment of Pol III (red), BRF1 (blue), and TFIIIC (dark green) at SNAR-A repetitive 
locus. Reads mapped with Bowtie to allow up to 15 ‘best’ alignments (bowtie-
bio.sourceforge.net).  (b,c) A single SNAR-A gene bears a point mutation, which allows us to 
query the locus by ChIP-qPCR, showing ~3.5-fold enrichment by (b) Pol III and (c) BRF1 over 
a negative control locus.  Green bars indicate positive controls that are known Pol III targets, 
blue bars are negative controls, and red bars are previously annotated genes that are newly 
shown to be bound by Pol III.  Error bars represent s.e.m. of three replicates.  y-axis 
represents relative starting template copy number based on standard curve of genomic DNA.  
(d) Novel Pol III (red), Pol II (turquoise), H3K4me3 (light green), and STAT1 (orange) bound 
regions. (Pol II, H3K4me3, STAT1 datasets from others1,2.)  Novel Pol III (red), BRF1 (blue), 
Pol II (turquoise), H3K4me3 (light green), and STAT1 (orange) bound regions overlapping the 
annotated MIR886 gene. (Pol II, H3K4me3, STAT1 datasets from others1,2.) Note that the total 
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RNA track (purple) shows a transcript made at this locus in HeLa cells.  No capped transcripts 
are present for this locus (data not shown).  The EST track (yellow) shows putative transcripts. 
The Pol III ChIP-chip track (dark green) shows the variably enriched (based on color intensity) 
tiles as assayed by ChIP-array. Consensus B-box is indicated (asterisk). (e) Quantitative PCR 
analysis of Pol III ChIP eluate in HeLa cells showing occupancy at MIR886 as shown by ChIP-
array and ChIP-seq. qPCR results graphed as in b,c. 
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Supplementary Figure 8 TFIIIC bound regions lacking Pol III initiation machinery cluster at 
Pol 2 promoters and have active chromatin.  (a) TFIIIC-bound sites lacking Pol III initiation 
machinery (Pol III, BRF1) show clustering at Pol II promoters, similar to active Pol III genes.  
(b–i) Class average maps for chromatin modifications/factors in HeLa show that TFIIIC-only 
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sites are associated with active chromatin, including Pol II, STAT1, and H3K4me3.  This is 
more prevalent in TFIIIC-bound sites overlapping repeat elements (e.g., MIR or Alu), although 
TFIIIC enrichment is similar whether a repeat is nearby or not.  The intersection fraction for 
each of these factor or mark bound regions with all TFIIIC-only sites is indicated in red. (j) 
MEME9 analysis identifies the G/A-rich sequence for TFIIIC-bound sites outside of predicted 
repeat elements (e.g., Alu, MIR), which typically lack a consensus B-box (bottom panel).  
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Supplementary Table 1. Primer sequences for ChIP-qPCR 
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Supplementary Data 1:  Lists of genes and enriched regions. 
Supplementary Data 2: Intersection analysis of genes and enriched regions. 
  
CHAPTER 3 
PP4 DIRECTLY DEPHOSPHORYLATES MAF1 TO  
COUPLE MULTIPLE STRESS CONDITIONS TO  
RNA POLYMERASE III REPRESSION 
Abstract 
Maf1 is required for general repression of RNA polymerase III (Pol III) 
transcription in response to diverse stresses, including nutrient deprivation, cell 
wall stress and DNA damage.  Interestingly, Maf1 is a phospho-integrator: it is 
phosphorylated and cytoplasmic under favorable growth conditions, whereas 
unfavorable growth conditions lead to dephosphorylation, nuclear accumulation, 
binding to Pol III at Pol III genes, and transcriptional repression.  Here, PP4 
complex (bearing catalytic Pph3) is established as the main Maf1 phosphatase 
for acute Pol III repression.  First, PP4 components are shown to have major 
roles in Maf1 dephosphorylation, nuclear localization, and Pol III repression.  
Second, PP2A is shown to contain Pph21/22, to lack Pph3, and to lack roles in 
acute repression or acute Maf1 dephosphorylation.  Third, PP4 binds directly to 
Maf1 in extracts and dephosphorylates Maf1 in vitro, with purified components.  
Finally, Pph3 mediates repression in response to diverse stresses, suggesting 
Maf1 and PP4 as co-integrators of cell nutrition, stress, and integrity for Pol III 
regulation. 




Transcription of the protein synthesis machinery (PSM) by all three RNA 
polymerases is coordinately responsive to nutrient availability and growth 
conditions.  The RNA polymerases work together to produce the PSM, 
accounting for ~80% of nuclear transcription in proliferating cells1.  Transcripts 
produced by each of these polymerases are required for protein synthesis, 
including ribosomal RNAs (mostly transcribed by Pol I except for 5S rRNA, which 
is transcribed by Pol III), ribosomal protein-coding mRNAs (transcribed by Pol II), 
and tRNAs (transcribed by Pol III).  In response to multiple stresses such as 
nutrient deprivation, repression of all components of the PSM is observed via the 
TOR pathway and other signaling pathways2,3.  Likewise, Pol III targets undergo 
rapid repression in nutrient deprivation and other stress conditions, an attribute 
important for regulation of growth and proliferation in yeast, as well as higher 
organisms.  In humans, many cancer types overexpress components of the Pol 
III machinery or its target RNA products, and Pol III targets are regulated by 
many tumor suppressors/oncogenes, including p53, Rb, and Myc4,5.  Studies in 
yeast have elucidated many conserved aspects of the regulation of Pol III.  While 
yeast does not possess homologous counterparts to these human tumor 
suppressors, they do share a conserved regulator with higher organisms: the 
protein Maf16.  Maf1 is emerging as a central regulator of Pol III transcription and 
is addressed in detail following a description of the Pol III machinery. 
Pol III transcribes short (< 550bp) noncoding RNAs involved in translation 
(e.g., tRNAs, Scr1), splicing (e.g., U6), and a variety of other functions7.  
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Normally, Pol III promoters in yeast reside in the transcribed region of the gene.  
A typical Pol III promoter consists of A- and B-box DNA consensus elements, as 
well as a stretch of at least four thymidine residues, which terminates 
transcription.  There are three subcomplexes in the basic Pol III machinery, each 
performing essential functions.  In simplified terms, TFIIIC complex recognizes 
the A- and B-boxes and recruits TFIIIB complex; TFIIIB contains the initiation 
protein TBP and together with TFIIIC recruits Pol III; and Pol III produces the 
RNA8.   
Regulation of Pol II transcription is exceptionally complex, due to the many 
thousands of targets that must be differentially activated or repressed under any 
particular condition.  In contrast, as the Pol III repertoire is largely (though not 
solely) dedicated to the PSM, a simpler mode of regulation is observed.  Also, in 
contrast to the Pol II system, Pol III promoters and the basal machinery in yeast 
have a “default on” state, requiring the master repressor Maf1 to attenuate the 
Pol III system during unfavorable conditions when the demand for PSM is 
decreased.  Notably, all repression signals for Pol III appear to converge on 
Maf1, which is required for repression of Pol III in response to nutrient 
deprivation, DNA damage, oxidative stress, and cell wall stress9,10.  Also, maf1 
mutant cells produce a higher basal level of tRNAs than WT cells.  Maf1 interacts 
in vivo with several subunits of the Pol III machinery, including Pol III components 
Rpc160, Rpc34, and Rpc82, as well as TFIIIB component Brf16,11,12.  Best 
characterized is the direct interaction of Maf1 with the N-terminus of Rpc160, 
shown first in vitro13 and verified by the crystal structure of Maf1 bound to Pol 
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III14.  Notably, Maf1 is not required for repression of ribosomal protein genes or 
Pol I-encoded ribosomal RNAs, suggesting that Maf1 is specifically dedicated to 
repression of Pol III9.  In summary, Maf1 functions as a master 
regulator/integrator that specifically represses Pol III transcription in response to 
multiple stresses by direct interaction with the Pol III machinery. 
Previous work by several labs has revealed important aspects of Pol III 
regulation by Maf1.  First, Maf1 is a phosphoprotein, and is phosphorylated and 
mostly cytoplasmic in favorable growth conditions12.  Phosphorylation by Sch9 
and PKA, and nuclear export by Msn5 are important for maintaining its 
cytoplasmic localization15-17. Upon stress, Maf1 is dephosphorylated, 
accumulates in the nucleus, and becomes highly enriched at Pol III target genes, 
as shown by whole-genome ChIP-on-chip studies12,13. Furthermore, in vitro 
systems have demonstrated that Maf1 can block recruitment of TFIIIB to 
preformed TFIIIC-DNA complexes11.  However, in vivo, Maf1 is also able to 
repress Pol III at a time when all three subcomplexes remain on DNA (TFIIIB, 
TFIIIC, and Pol III).  The data can be reconciled by postulating two phases of 
repression: 1) the acute phase (within 30 min of stress/nutrient deprivation), 
during which Maf1 associates with Pol III on DNA and represses transcription, 
and 2) the prolonged phase, during which TFIIIB and Pol III are displaced from 
DNA and recruitment of new active Pol III complexes is inhibited.  As Pol III 
specifically interacts with the hypophosphorylated form of Maf1, it is likely that the 
major role of Maf1 dephosphorylation is in the acute phase of repression12. 
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Since Maf1 dephosphorylation is a common mechanism in all reports of 
Maf1-dependent repression of Pol III to date, the identity of the phosphatase(s) 
and how it/they are regulated is a central question.  As Pol III repression in 
diverse unfavorable conditions (representing multiple signaling pathways) each 
require Maf1, diverse phosphatases from each of these pathways could, in 
principle, act on Maf1.  Alternatively, one phosphatase could account for the 
majority of Maf1 dephosphorylation in response to all Pol III-repressive stresses.  
Many phosphatases have been tested for their requirement in dephosphorylation 
of Maf1, with one report strongly pointing to the PP2A family of serine/threonine 
phosphatases13.  These phosphatases are interesting as a group, since they are 
regulated by Target of rapamycin (TOR), and specific inhibition of TOR nutrient 
signaling with the macrolide antibiotic rapamycin induces rapid inhibition of Pol III 
transcription18.  The regulation of PP2A phosphatases by TOR suggests a 
possible mechanism of integrating nutrient availability and other stresses to 
dephosphorylation of Maf1.  Regulation of PP2A family phosphatases by TOR 
occurs via the protein Tap42.  Tap42 interacts with the PP2A family catalytic 
subunits Pph21, Pph22, Pph3, and Sit419-21 and this interaction is reinforced by 
TOR phosphorylation of Tap4222.  Upon inhibition of TOR by the drug rapamycin 
or by poor nutrient source, the phosphatases become active, probably by 
dissociating from Tap42 and associating in their respective holoenzymes23.  
While Sit4 is not involved in Pol III repression3,12, a potential role for Pph21/22 or 
Pph3 has been reported13.  Pph21, Pph22 and Pph3 have frequently been 
reported as alternative catalytic subunits of the PP2A phosphatase complex.  
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Notably, PP2A has been described as the Maf1 phosphatase, as the triple 
catalytic mutant of phosphatases pph21!, pph22-ts, and pph3! is defective for 
Maf1 dephosphorylation and Pol III repression.  However, in other work, the 
PP2A scaffold and catalytic mutants tpd3! and pph21!pph22!, respectively, 
were not defective for Maf1 dephosphorylation, initially raising the possibility that 
PP2A may not be the Maf1 phosphatase12.  Furthermore, there is a growing body 
of evidence supporting Pph3 as part of an evolutionarily conserved phosphatase 
complex, Protein Phosphatase 4 (PP4).  Pph3 homologs have been studied in 
amoeba, budding yeast, human, worms, and fruit flies and found to have a 
conserved role in the regulation of the DNA damage response24-26.  In addition, 
interaction of Pph3 (or its homologues) with PP4-specific subunits has been 
shown in humans, S. cerevisiae, D. discoideum, and C. elegans24-26.  In this 
study, we demonstrate that Pph3 is the catalytic subunit of PP4 and not PP2A in 
yeast.  We then provide multiple lines of evidence that the PP4 complex (Pph3 
and certain other components) is the major and direct phosphatase of Maf1 in 
response to multiple stress pathways in yeast. Notably, Pph3 is needed for acute 
repression in response to diverse stresses, suggesting that Maf1 and PP4 are 
co-integrators of nutrition, stress, and integrity. Finally, we develop and utilize a 
Maf1-Pol III fusion protein that has proven useful in identifying functional PP4 
components, and which may be a valuable tool in uncovering and characterizing 
other components involved in Pol III repression. 




A Maf1-Rpc160 Fusion Recapitulates Maf1-dependent  
Pol III Transcriptional Repression 
Our initial goal was to determine the factors required for Maf1-dependent 
execution of Pol III transcriptional repression.  To begin, we created a genetic 
tool: a fusion protein involving Maf1 fused to the amino terminus of the large 
subunit of RNA Pol III (Rpc160), a subunit that directly binds Maf1 during 
repression13,27(see Introduction).  The expressed Maf1-Rpc60 protein is expected 
to localize to the nucleus, interact with the Pol III machinery, and attenuate its 
activity–leading to reduced growth–with the relief of repression as the basis for 
the screen.  Maf1-Rpc160 contains the entire open reading frame (ORF) of 
MAF1, a linker of 10 or 25 (not shown) amino acids (aa), the entire ORF of 
RPC160, and a 3XHA tag (Fig. 3.1A).  The GAL1 promoter enables galactose-
inducible expression of Maf1-Rpc160, and a control construct was also created 
(lacking Maf1) that expresses only tagged Rpc160. 
In galactose-containing medium, the Maf1-Rpc160 fusion and Rpc160 
constructs express proteins at the expected molecular weights of ~212kDa and 
~167kDa, respectively (data not shown).  To determine whether the fusion 
protein affects Pol III transcription, RNA was isolated from cells grown in glucose 
or galactose for 4 h.  Northern blotting was performed using probes 
complementary to U4 (control Pol II target) and pre-tRNALeu3 (a Pol III target); 
pre-tRNAs are examined to distinguish new transcription from highly stable 
spliced tRNAs.  As expected, in conditions where the fusion protein is expressed,  




















































































Figure 3.1 A Maf1-Rpc160 fusion functionally represses Pol III transcription and 
is a screening tool to identify Maf1-dependent repressors of Pol III.  (A) 
Constructs of galactose-inducible Rpc160 or Maf1-Rpc160 fusion.  (B) 
Expression of the Maf1-Rpc160 fusion but not Rpc160 represses pre-tRNALeu3 
transcription.  (C) Quantification of lanes 5-8 of (B) as a ratio of tRNA/U4 band 
intensity with Rpc160 set to 1.  Error bars represent standard deviation.  (D) 
Expression of the Maf1-Rpc160 fusion but not Rpc160 confers a dominant 
growth defect.  (E) The fusion growth defect is dependent on a functional Maf1.  
Null missense mutations in the Maf1 portion of the fusion partially suppress the 
fusion growth defect.  (F) Partial suppression of the growth defect in triple mutant 
pph21" pph22-172 pph3" on plates containing galactose validates the Maf1-
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new tRNALeu3 production is reduced to approximately 25% of levels seen in 
induction of Rpc160 alone (Fig. 3.1B, C), which equates to approximately 10% of 
normal levels (data not shown).  This demonstrates that the fusion protein 
confers Pol III transcription. 
We also tested the fusion for growth inhibition on galactose-containing 
plates.  The reduction in tRNA levels by the fusion protein correlated with a 
growth defect on galactose-containing plates, as determined by colony size (Fig. 
3.1D, left and middle).  This is a dominant growth defect as it is seen in WT and 
rpc160! [RPC160+] cells, both of which also express the WT version of Rpc160 
(Fig. 3.1D, middle panel).  A similar growth defect was found for the small (10aa) 
and large (25aa) linker sizes (data not shown), and future experiments were 
performed with the small linker fusion.  The fusion is functional, as it 
complements rpc160! when loss of the WT Rpc160 (URA3) vector is enforced 
with FOA (Fig. 3.1D, right).  In conclusion, the functional consequence of 
reduced expression of Pol III targets is a slow-growth phenotype, which we have 
termed the “fusion growth defect.”   
Two controls are needed to ensure that the magnitude of the growth 
defect is meaningful, and not trivial. First, growth inhibition may be solely due to 
overexpression of Maf1 in the fusion, with no need for the fusion to Rpc160.  
However, no growth defect was observed on galactose-containing plates, 
compared to empty vector controls (data not shown).  Second, fused Maf1 may 
simply impair Rpc160 by a nonspecific mechanism.  To test this, we created 
missense mutations in the Maf1 portion of the fusion construct, utilizing mutations 
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(maf1-104 and maf1-124) that create strong hypomorphic alleles and resist 
dephosphorylation, based on previous studies12.  Remarkably, both rescued the 
fusion growth defect, even while in a fusion context (Fig. 3.1E), suggesting that 
the fusion growth defect requires a functional Maf1 fused upstream of Rpc160 
(and possibly proper phosphorylation dynamics) for full growth repression.  
To evaluate the main candidate phosphatases for Maf1-dependent Pol III-
repression, we transformed the fusion construct or control plasmids into a triple 
phosphatase mutant lacking Pph3 and the PP2A catalytic subunit Pph21, and 
bearing a hypomorph of Pph22.  This strain has been shown to be defective for 
normal Maf1 dephosphorylation and Pol III repression13.  The fusion growth 
defect was moderately rescued in this strain (Fig. 3.1F), suggesting that the 
activity of the fusion protein can be regulated by phosphorylation and that this 
construct can be used as a tool to look for candidates in the repression pathway.   
Pph3 Is Required for Maf1-dependent Acute-phase  
Repression of Pol III Transcription 
We then used the fusion tool to address the important question of the role 
of Pph3, and whether it resides in PP4 or PP2A (see Introduction).  To 
investigate the role of Pph3 in Maf1-dependent repression of Pol III, we assayed 
WT and pph3! null strains by 1) Western blot, 2) Northern blot, 3) our fusion 
growth assay, and 4) immunofluorescence (IF). 
To determine whether Pph3 is required for dephosphorylation of Maf1, 
HA-tagged Maf1 controlled by its endogenous promoter was transformed into WT 
or pph3! strains.  Extracts from untreated cells or cells treated with nutrient 
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deprivation (ND), or rapamycin (125 nM) for 25 min were subjected to Western 
blot.  Cells were pretreated with cycloheximide (CHX) to examine resident, but 
not newly translated, Maf1.  Pph3 is required for dephosphorylation of Maf1 in 
response to nutrient deprivation and inhibition of TOR, as phosphorylated Maf1 
persists following ND or rapamycin treatment (Fig. 3.2A).   
When WT cells are treated with rapamycin but not ND, total Maf1 levels 
decrease (Fig. 3.2A), suggesting there may be two modes of Maf1 regulation by 
rapamycin: protein stability and dephosphorylation.  Importantly, Maf1 
degradation in rapamycin treatment also occurs in pph3! cells (Fig. 3.2A and 
data not shown), suggesting that Pph3 is required for rapamycin-induced acute 
dephosphorylation but not degradation of Maf1. 
To determine whether inability to dephosphorylate Maf1 in pph3! cells 
would confer a Pol III repression defect, we isolated RNA from WT, pph3!, and 
complemented pph3! [PPH3] (pph3! mutant with WT Pph3 plasmid). As 
determined by Northern blot, pph3! is defective for full repression of Pol III 
transcription in nutrient deprivation (Fig. 3.2B, C).  This defect was 
complemented by a WT cloned version of Pph3 (FLAG-tagged at the N-terminus) 
(Fig. 3.2B, C).  Of note, at longer time-points (e.g., 1 h), repression of Pol III 
occurs in pph3! as well as in WT, suggesting that dephosphorylation of Maf1 is 
important in the acute phase of repression but not prolonged repression (data not 
shown).  Importantly, we see rescue of the fusion growth defect in the pph3! null 
(Fig. 3.2D), consistent with an independent role for Pph3 in Maf1-dependent 
repression of Pol III.   




Figure 3.2 Pph3 plays a nonredundant role in global Pol III repression.  (A) 
Nutrient deprivation (ND) and rapamycin treatment (Rap) cause 
dephosphorylation of Maf1 in WT but not pph3" mutant strain.  (B) Northern blot 
showing repression of pre-tRNALeu3 transcription in WT strain (top) in response to 
ND.  Repression is absent in maf1", attenuated in pph3" and restored by 
complementing with Pph3 on a plasmid.  (C) Quantification of (B) as a ratio of 
tRNA/U4 band intensity.  Values represent the average of band intensities from 
two replicate blots.  Error bars represent the standard deviation.  Significance 
value calculated as a comparison of WT to mutant strain by Student’s t-test.  * p-
value<0.05 (D) The fusion growth defect is partially suppressed in pph3" strain.  
(E, F) Nuclear localization of Maf1-HA in response to nutrient deprivation in (E) 
WT and (F) pph3".  Localization of Maf1 to the nucleus is delayed in pph3" 
compared to WT.  (G) Distribution of Maf1 localization in WT and pph3" strains 
at t = 0, 30 min, and 6 h.  Significance values calculated as difference between 
nuclear (N>>C, N>C) and cytoplasmic (C>N, C!N) Maf1 in WT and pph3" using 
Fisher’s exact test. 
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To determine whether nuclear translocation of Maf1 is affected in pph3! 
mutants, WT and pph3! cells were treated with ND and examined after 30 min 
and 6 h.  By IF, pph3! shows a defect/delay in the translocation of Maf1 to the 
nucleus compared to WT (Fig. 3.2E-G).  In untreated cells, the distribution of 
Maf1 is similar in WT compared to pph3! cells.  After 30 min treatment, Maf1 
localization becomes more nuclear in the WT strain, but in the pph3! strain, Maf1 
localization appears unchanged from the untreated state (Fig. 3.2G).  After 6 h of 
treatment, the Maf1 localization profiles appear similar in WT and pph3!, 
consistent with a role for Pph3 in acute but not prolonged repression of Pol III 
transcription. 
Pph3 Is in Protein Phosphatase 4 but not  
Protein Phosphatase 2A 
To understand the regulation of Pph3 in stress-activated repression of Pol 
III, we determined which phosphatase complex(es) Pph3 resides in—PP4 or 
PP2A.  Pph3 can stably interact with several yeast proteins in vivo, including 
Psy2 and Psy424.  The complex of Pph3, Psy2 and Psy4 (or their homologues) is 
one form of Protein Phosphatase 4 (PP4).  Whether yeast Pph3 can bind to the 
PP2A scaffold has not been tested.   
To test whether Pph3 could interact with Tpd3, we transformed strains 
with Pph3-FLAG and/or Tpd3-myc constructs and prepared extracts.  
Immunoprecipitation (IP) of Pph3 with FLAG-agarose beads captures 
approximately 90% of the Pph3 in the extract, yet no Tpd3 is found to be 
associated (Fig. 3.3A).  To ensure that the conditions allow Tpd3-phosphatase  
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Figure 3.3 Pph3 is part of the Protein Phosphatase 4 complex (PP4) but 
not PP2A. (B) Pph3 does not interact with Tpd3.  (A) Pph21 binds to the 
PP2A scaffold Tpd3.  (C) Pph3 interacts with the PP4-specific subunit 
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association, a control IP was performed between Tpd3 and Pph21 under the 
same conditions.  Strains transformed with the Tpd3-myc construct and Pph21-
HA show a specific physical interaction (Fig. 3.3B).  Also, as a positive control, 
we tested whether our Pph3 construct could interact with Psy2, a PP4-specific 
subunit.  Under the same conditions, we found that Pph3 binds to Psy2 (Fig. 
3.3C), confirming its presence in the PP4 complex.  These results show that 
yeast Pph3 is present in PP4 but not in PP2A under the conditions tested.  
Pol III Repression Requires PP4 Subunit Psy2  
but not PP2A Subunits 
In order to determine the relative functional roles of PP4 and PP2A 
regulatory subunits in Maf1-dependent repression of Pol III, we assayed mutants 
of regulatory subunits for each complex with our fusion growth assay.  We also 
analyzed the ability of these mutants to dephosphorylate Maf1 by Western blot.   
Pph3 associates stoichiometrically with Psy2 and Psy4 (ref. 28 and data 
not shown); therefore, we tested mutants lacking either (or both) of these genes 
to determine whether either acts with Pph3 in repression of Pol III.  In screening 
these PP4 subunit mutants, we saw that psy2" mutants rescue the fusion growth 
defect to the same degree as seen in the pph3" mutant (Fig. 3.4A, left three 
panels).  In contrast, The psy4" mutant shows little or no rescue of the fusion 
growth defect and no additive effect when combined with the psy2" mutation, 
illustrating that Psy4 is not required for Pol III repression in this assay (Fig. 3.4A, 
right three panels).  Importantly, Psy2 is required for dephosphorylation of Maf1 
as is Pph3 (Fig. 3.4B).  By Western blot analysis, we see that Psy4 is not  
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Figure 3.4 PP4 complex members play a role in steps of Pol III repression.  (A) 
The fusion growth defect is partially rescued in some PP4 mutant strains. (B) 
Maf1 is dephosphorylated in WT but not psy2" mutant in response to nutrient 
deprivation (ND) and rapamycin (Rap).  Psy4 is not required for 
dephosphorylation of Maf1.  (C) Psy2 and Pph3 can interact in the absence of 
Psy4.  (D) Pph3 and Psy2 are required for reduction of nascent tRNA levels in 
ND, Rap and MMS treatments.  Panels on the right are a quantification of two 
replicates as a ratio of tRNA/U4 band intensity, with T = 0 set to 1; panels on the 





   
  
75
required for dephosphorylation of Maf1 (Fig. 3.4B), consistent with a view that a 
Pph3-Psy2 complex is acting to direct dephosphorylation of Maf1.  This result 
suggests that Pph3 and Psy2 might interact in the absence of Psy4.  Indeed, we 
performed an IP of Pph3 and Psy2 in the psy4" strain and found clear interaction 
(Fig. 3.4C).   
To test whether Psy2 is required for repression of Pol III at the 
transcriptional level, we isolated RNA from WT, pph3", and psy2" strains treated 
with ND, rapamycin, or MMS, and assayed for new Pol III transcription by  
Northern blot.  We found that psy2" is defective for Pol III repression in the acute 
phase in a magnitude similar to pph3" (Fig. 3.4D). 
PP2A is a heterotrimeric complex composed of the scaffold (Tpd3), a 
catalytic subunit (Pph21 or Pph22) and a regulatory subunit (Cdc55 or Rts1)29.  
Since Pph21 and Pph22 are essentially redundant, we created a double null in 
the S288C background to test in our assays.  Notably, when the double 
pph21"pph22" mutant was tested in the fusion growth assay, it showed no 
rescue and grew more slowly than the WT strain with the fusion construct (Fig.  
3.5A, left two panels).  A similar result was obtained with the tpd3" mutant (Fig. 
3.5A, third panel).  Furthermore, mutation in either regulatory subunit of PP2A 
shows no rescue of the fusion growth defect (Fig. 3.5A, right two panels).  
Previous results showed that W303 background pph21"pph22" and tpd3" 
mutants12 are not defective for dephosphorylation of Maf1 in response to nutrient 
deprivation.  Because strain background differences have been reported for 
different PP2A family phosphatase mutants due to variable SSD1 alleles30,31, we  
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Figure 3.5 Pol III repression requires PP4 accessory factors, but not PP2A 
subunits.  (A) The fusion growth defect remains or is intensified in PP2A mutant 
strains.  (B) Neither Tpd3, Pph21, nor Pph22 are required for dephosphorylation 
of Maf1 in nutrient deprivation (ND) or rapamycin (Rap) treatment.  PP4-
associated factors Tip41 and Rrd1 are required for dephosphorylation of Maf1 in 
ND and Rap, but PP2A-associatd Rrd2 is not required. (C) The fusion growth 
defect is rescued in rrd1" and tip41" mutants, but not rrd2", correlating to 
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tested pph21"pph22" and tpd3" mutants in S288C background and found them 
to similarly have the ability to dephosphorylate Maf1 in response to nutrient 
deprivation (ND) or rapamycin treatment (Fig. 3.5B).  The lack of rescue of PP2A 
mutants in the fusion growth assay and the ability of PP2A mutants to 
dephosphorylate Maf1 strongly suggest that PP2A is not the major phosphatase 
involved in Maf1-dependent repression of Pol III. 
The results above show a high correlation between mutants that rescue 
the fusion growth defect and those defective in the dephosphorylation of Maf1 
(Fig. 3.4B).  In order to further investigate the different roles of PP4 and PP2A, 
we used the fusion construct to screen other genes whose protein products have 
been shown to be in complex with catalytic subunits of these complexes at 
substoichiometric levels.  The yeast protein tyrosyl phosphatase activators Rrd1 
and Rrd2 are conserved proteins involved in activating the PP2A-like family of 
phosphatases32.  Rrd1 shows a preference for interacting with PP2A-like 
phosphatases Pph3, Sit4 and Ppg1, while Rrd2 only interacts with Pph21 and 
Pph2232.  Consistent with a role for Rrd1 in activating PP4, rrd1" mutants show  
rescue of the fusion growth defect (Fig. 3.5C) and are defective for Maf1 
dephosphorylation in ND and rapamycin treatment (Fig. 3.5B).  In contrast, rrd2" 
mutants show an enhanced fusion growth phenotype similar to pph21"pph22" 
or tpd3" mutants and are not defective for Maf1 dephosphorylation by Western 
blot in ND or rapamycin (Fig. 3.5B,C).  Again, this is consistent with PP4 as the 
major phosphatase involved in Pol III repression. 
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Tip41 is a member of the TOR signaling pathway that physically interacts 
with PP2A family phosphatases, including Pph3, Pph21/22, and Sit420,24,33.  
Upon inhibition of TOR, Tip41 binds to the phosphatases and activates them20,24.  
Tip41 interacts with PP4 at substoichiometric levels and a role for Tip41 in Pph3 
regulation has been implicated in the DNA damage response24.  When the fusion 
construct is transformed into tip41" mutants, we see rescue of the growth defect, 
suggesting that Tip41 plays a role in activation of Maf1, likely in concert with 
Pph3 (Fig. 3.5C).  tip41" mutants were also defective in dephosphorylation of 
Maf1, consistent with the results of the fusion growth assay (Fig. 3.5B). 
Maf1 Interacts Directly with Pph3 
Since Maf1 remains phosphorylated in pph3" and psy2" strains, it 
seemed likely that PP4 could dephosphorylate Maf1 directly, although there was 
a possibility that PP4 could regulate Maf1 indirectly, via a different phosphatase.  
To distinguish between these two models, we determined whether Maf1 could 
interact physically with Pph3.  Because interactions between an enzyme and its 
substrate are often transient and difficult to detect, we attempted to maximize the 
chance of detecting an interaction by cross-linking the cells with 1% 
formaldehyde.  We cloned Pph3 under the control of the MET25 promoter in 
order to overexpress the protein in medium lacking methionine. Here, HA-tagged 
Maf1 was co-expressed with FLAG-tagged Pph3.  We looked for an interaction 
by co-IP in unstressed cells as well as cells stressed with MMS for 30 min to 
activate the phosphatase.  In both stressed and unstressed cells, we detect 
specific interaction of Pph3, enriched 3-4-fold above background (Fig. 3.6A,B).   




Figure 3.6 Pph3 dephosphorylates Maf1 directly.  (A, B) Maf1 interacts with 
Pph3 in (A) unstressed cells and (B) MMS-treated cells. (C) Psy2-GFP strain 
grows well on plates with camptothecin, thus the PP4 complex is functional.  
Pph3-GFP fusion renders PP4 nonfunctional, as indicated by growth on 
camptothecin similar to pph3".  (D) Psy2-GFP localizes to the nucleus and cell 
membrane in unstressed cells.  (E) Pph3-TAP complexes (but not Psy2-TAP 
complexes from pph3" background) are active on purified phosphorylated Maf1 
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We detect only a small fraction of total Maf1 associated with Pph3 (<5%), which 
may be due to the difficulty of capturing enzyme-substrate interactions by IP.  
The level of association is similar in uncrosslinked extracts (data not shown), 
suggesting that the interaction is not an artifact of crosslinking nonspecific 
proteins. 
PP4 Subunit Psy2 Is Localized in the Nucleus 
 As already mentioned, PP4 plays a role in DNA damage, which is one 
cellular perturbation that causes Pol III repression.  PP4 dephosphorylates 
Rad53 and "H2AX in order to recover from the intra-S cell cycle checkpoint 
induced by DNA damage28,34.  Recent data show that in the nuclear exportin 
msn5" mutant strain, Maf1 is constitutively localized in the nucleus but still 
requires dephosphorylation to repress Pol III16.  This suggests that the 
phosphatase of Maf1 must be capable of localizing to the nucleus.  All of the 
known substrates of yeast PP4 are nuclear proteins34,35 (e.g., Rad53, !H2AX), 
and PP4 is activated towards these substrates in DNA-damaging conditions, 
putting PP4 in the proper time and place for filling the role of a Maf1 
phosphatase.  
In order to determine where Pph3 acts for its cellular function, we created 
nuclear and cytoplasmic versions of Pph3 (with either a nuclear localization 
sequence or nuclear export sequence encoded in the protein) and transformed 
them into pph3" cells.  Both versions complement the null phenotype as well as 
WT Pph3 by growth on camptothecin plates and by pre-tRNA repression 
Northern blots (data not shown).  This suggests that the action of the enzyme for 
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its DNA damage function, as well as its Maf1 dephosphorylation function can be 
in the nucleus or the cytoplasm.  Alternatively, Pph3 activity could be required in 
a particular compartment, but there could be leaky mislocalization of the Pph3 
proteins that is sufficient for complementing activity.   
 We also attempted to enhance the fusion growth defect by overexpression 
of WT Pph3 by growth of strains with Pph3 under control of Met15 promoter on 
plates lacking methionine, to no effect.  Interestingly, overexpression of 
cytoplasmic Pph3 caused suppression of the fusion growth defect (data not 
shown).  As this phenocopies the growth ability of a pph3" strain with the fusion, 
it could be that overexpression of Pph3 in the cytoplasm titrates limiting enzyme 
complex members (e.g., Psy2) into the cytoplasm, causing nuclear PP4 function 
to be abrogated.  This could suggest that Pph3 enzyme activity causing the 
fusion growth defect is required in the nucleus.  This may reflect the natural 
localization requirement for enzyme activity, or it could reflect the requirement of 
enzymatic activity in our fusion assay only, as the fusion likely localizes in the 
nucleus (as evidenced by its complementation of rpc160! null lethality [Fig. 3.1D, 
third panel], which suggests it can incorporate into Pol III complexes and provide 
activity).   
 To determine the localization of PP4, we obtained strains with GFP-
tagged Pph3 or Psy2.  To test whether the GFP fusion proteins allow a functional 
phosphatase, the growth ability for the strains was assayed on plates containing 
camptothecin.  Psy2-GFP strains show growth similar to WT, although Pph3-
GFP strains show growth similar to pph3" (Fig. 3.6C), suggesting that GFP 
   
  
82
fused to Psy2 but not Pph3 permits a functional complex with proper localization.  
By fluorescent microscopy, we see that Psy2-GFP shows strong nuclear 
localization, consistent with the predicted location of the Maf1 phosphatase (Fig. 
3.6D).  This suggests that Maf1 dephosphorylation most likely occurs in the 
nucleus, and the accumulation of Maf1 in the nucleus during stress is due to the 
inability to shuttle dephosphorylated Maf1 out of the nucleus16.   
PP4 Dephosphorylates Maf1 In Vitro 
 In addition to the genetic and molecular data shown above, we attempted 
to reconstitute the dephosphorylation of Maf1 by PP4 in vitro.  To do this, we 
incubated IgG-bound complexes from a Pph3-TAP strain, or a Psy2-TAP strain 
with pph3" null as a negative control.  Both Pph3-TAP and Psy2-TAP have been 
shown previously to bind stably to the other main components of PP4 (e.g., 
Pph3, Psy2, and Psy4) and their purified complexes have phosphatase activity, 
unless PPH3 is deleted28.  To verify activity of the enzyme complex, we used 
phosphorylated Rad53, which was shown previously to be a native substrate28.  
As seen in Figure 3.6E (bottom panel), Pph3-TAP is active at 2 and 8 h against 
Rad53 and Psy2-TAP pph3" complexes are not.  By quantifying the change in 
Rad53 mobility, at 2 h, Pph3-TAP has 22.2% (±0.7) of the activity seen by 
lambda phosphatase and 34.8% (±3.1) of the lambda activity at 8 h (when 
comparing the change in the bottom band as a percentage of total Rad53 signal 
per lane; see Methods).  Likewise, Pph3-TAP complexes are active at 8 h 
against phosphorylated Maf1 (Fig. 3.6E, top panel).  Because of the poor 
separation of the phosphorylated species of Maf1 compared to Rad53, it is 
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difficult to see much difference in phosphorylation at 2 h.  The quantified change 
in Maf1 mobility shows that at 2 h, the Pph3-TAP complex has 5.3% (±3.7) of the 
activity of lambda phosphatase and 43.0% (±4.1) activity at 8 h.  The Psy2-TAP 
pph3" complexes show <4% of the activity of lambda phosphatase on both 
Rad53 and Maf1 at 2 h and 8 h.  Taken together, these data show that a PP4 
complex containing Pph3 can dephosphorylate Maf1. 
Pph3 Is an Integrator of Multiple Signals for  
Maf1 Dephosphorylation 
The simplest explanation for regulation of Maf1 dephosphorylation during 
acute repression consists of a single phosphatase complex acting in response to 
all stresses, but there could potentially be multiple phosphatases regulating Maf1 
in response to different stresses.  To address this, we sought to test for the 
requirement of Pph3 for dephosphorylation of Maf1 in other, some of which have 
been reported to repress Pol III.  Extracts were prepared from WT and pph3" 
cells stressed with the DNA-damaging agent methyl methanesulfonate (MMS), 
cycloheximide (CHX), chlorpromazine (CPZ), dithiothreitol (DTT), glycerol, 
glucose deprivation, nitrogen deprivation (ND), amino acid deprivation, or 
phosphate deprivation, all of which are associated with Pol III repression (except 
phosphorus deprivation)3.  Phosphorus deprivation was included as a stress 
since it causes nuclear accumulation of tRNAs, similar to DNA damage and 
amino acid deprivation36-38, although whether it causes Pol III transcription arrest 
has not been tested.  Glucose deprivation is similar to ND treatment (i.e., both 
lack glucose) and produces similar results, in that Pph3 is required for 
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dephosphorylation of Maf1 (Fig. 3.7A).  Maf1 dephosphorylation in cells with 
glycerol as the main carbon source is also Pph3-dependent (Fig. 3.7A).  
Endoplasmic reticulum stress with DTT and cell wall stress with CPZ are also 
Pph3-dependent stresses (Fig. 3.7B).  The remaining stresses tested have been 
reported to repress Pol III (except phosphorus limitation), but whether they are 
accompanied by dephosphorylation of Maf1 has not been reported.  As seen in 
CHX treatment, dephosphorylation of Maf1 begins between 30 and 60 min, 
therefore in treatments longer than 30 min, CHX is not included, in order to 
ensure the dephosphorylation we see is due to the stress and not the 
supplemental CHX.  Notably, this dephosphorylation seen in CHX is Pph3-
dependent (Fig. 3.7C).  Pph3 is also required for full dephosphorylation of Maf1 
in nitrogen, amino acid, and phosphorus deprivation treatments (Fig. 3.7D–E).  
These findings demonstrate that the Pph3 phosphatase complex PP4 is able to 
integrate multiple nutrient and stress signals to effect bulk dephosphorylation of 
Maf1.   
Discussion 
PP4 as an Integrator of Multiple Stress Conditions 
For Dephosphorylation of Maf1 
As Maf1 is a conserved, central regulator of Pol III and its phosphorylation 
status is correlated with activity of Pol III in response to all known Pol III-
repressive stresses tested thus far, it is important to understand how 
phosphorylation of Maf1 is regulated.   
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Figure 3.7 Pph3 is required for dephosphorylation of Maf1 in multiple stress 
conditions.  (A-E) Maf1 dephosphorylation requires Pph3 in (A) glycerol as 
carbon source, no carbon source, (B) extended cycloheximide (CHX), (C) methyl 
methanesulfonate (MMS), chlorpromazine (CPZ), dithiothreitol (DTT), (D) 
nitrogen deprivation (-N), amino acid deprivation (-aa), and (E) phosphorus 
deprivation (-P).   
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Here, we show that Pph3 is required for full repression of Pol III 
transcription in response to multiple stresses.  Pph3 has previously been 
identified as a potentially important phosphatase subunit involved in regulation of 
Maf113, but whether it could function independently of PP2A catalytic subunits, as 
well as the identity of the complex of which it was a member in this process had 
not been previously determined.  Here, we provide evidence that Maf1 is 
dephosphorylated by Protein Phosphatase 4, composed of Pph3 and Psy2 (plus 
potential accessory factors Rrd1 and/or Tip41), in response to multiple stresses 
that lead to Pol III repression.  This is further evidenced by the direct interaction 
of Pph3 and Maf1 herein detected by immunoprecipitation.  Previous work 
investigating the role of Pkc1 in repression of Pol III showed that Pkc1 was 
required in nutrient deprivation but not rapamycin treatment12, suggesting that 
these treatments converge on Maf1 via different pathways.  This result, as well 
as the fact that there is a multitude of different stresses that can cause Pol III 
repression, argues that there could be multiple phosphatases regulating Maf1.  
We show here instead that a single phosphatase, PP4, is able to regulate 
phosphorylation of Maf1 in response to rapamycin, DNA damage, 
chlorpromazine, cycloheximide, and multiple types of nutrient deprivation.   
Conserved Role for PP4 in the Stress Response 
PP4 plays a role in the environmental stress response in many other 
species.  PP4 has been shown to play a role in the DNA damage response in 
multiple species, including yeast, human, C. elegans, and Drosophila24,25.  This 
has been shown to be in part via interaction with and dephosphorylation of 
   
  
87
Rad53, which allows the cell to overcome G2/M arrest28.  The human form of 
Pph3—PP4C—interacts with the human form of Tap42—IGBP1—suggesting 
that the involvement of human PP4 in mTOR and nutrient signaling might be 
conserved in humans39.  Human PP4 was found to play a role in the 
inflammatory response via activation of nuclear factor-"B (NF-"B) p65 and c-Jun 
N-terminal kinase (JNK) in tumor necrosis factor (TNF-#) signaling40,41.  In 
Dictyostelium discoideum, the PP4 complex is activated in response to starvation 
conditions in order for the cells to differentiate into fruiting bodies26,42.  In addition 
to its role in the DNA damage response, C. elegans smk-1 (homologue of Psy2) 
is required for the response to oxidative and innate immune stress required for 
long-lived worms43.  Given the role for PP4 in the environmental stress response 
of higher organisms, it will be interesting to see if PP4 also plays a conserved 
role in dephosphorylation of Maf1. 
PP4 Versus PP2A in Pol III Regulation 
Initially, PP2A appeared to be a good candidate for regulation of Pol III.  It 
was shown that in tpd3! cells, Pol III transcription was inhibited44,45.  In vitro 
studies have shown that compared to free PP2A phosphatase subunits, the 
scaffold-catalytic dimer has less activity towards nonphysiological substrates46, 
leading to the conclusion that Tpd3 is an inhibitor of PP2A and that tpd3! cells 
have overactive PP2A.  However, genetic data suggest that Tpd3 is rather 
required for proper activity of PP2A, as tpd3! cells have similar phenotypes to 
pph21!pph22! cells47.  Instead of being required for repression of Pol III, the 
reduction in Pol III transcription seen in tpd3! cells suggests that PP2A is 
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required for proper Pol III transcription3.  This idea can be explained with the 
following: since tpd3! cells have a slow growth phenotype and are lacking 
appropriate PP2A activity, it is likely that certain stress pathways are activated, 
which could activate PP4 and lead to repression of Pol III.  Furthermore, it has 
been suggested by some that Pph3 is an alternative catalytic subunit of PP2A, 
although much evidence suggests that this is not the case.  For example, initial 
reports showed that the rabbit homolog of Pph3, PPX, cannot bind to the 
homolog of the PP2A scaffold, PP2AA, in vitro48.  In contrast, recent studies in 
human cells using quantitative mass spectrometry report that there is a 
detectable amount of PP4C in complex with PP2AA and a few regulatory subunits 
of PP2A49-51.  However, the low ratio of PP2A scaffold/regulatory subunits in 
complex with PP4C versus canonical PP2A catalytic subunits—approximately 
1:60—suggests this type of complex is not abundant51.  Importantly, there is no 
evidence suggesting that PP2A catalytic subunits can bind to PP4-specific 
subunits, such as Psy2.  Here, we confirm that Pph3 is not a regular component 
of yeast PP2A and suggest rather that it is the catalytic subunit of PP4. 
Potential Mechanisms for Regulation of PP4 
In addition to the core phosphatase of Maf1, we also identify the proteins 
Tip41 and Rrd1 as potential accessory factors to PP4 in dephosphorylating Maf1.  
Tip41 was suggested to act in concert with PP4 in DNA damage24 and has been 
shown to activate Sit4 and PP2A catalytic subunits towards their substrates 
Gln320 and Msn233, respectively.  Rrd1 is the yeast homologue of human 
phosphotyrosyl phosphatase activator (PTPA) and is able to activate PP2A 
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family phosphatases in vitro32, including Pph3.  PTPA has been shown to have 
prolyl isomerase activity, by which it activates PP2A52.  PTPA in complex with the 
catalytic subunit acts as a composite ATPase, required for its ability to activate 
PP2A53.  The proline residue in human PP2AC required for this reactivation is 
Pro190, which is conserved in all yeast PP2A and PP2A-like phosphatase 
subunits, suggesting that a similar mechanism of activation could be occurring in 
yeast.  It will be interesting to determine how PP4 is regulated by these or other 
proteins to dephosphorylate Maf1.   
DNA damage often causes replication fork arrest, which appears to be the 
causative insult leading to repression of Pol III in response to DNA damaging 
agents54.  Replication fork arrest-induced repression of Pol III was shown to be 
Maf1-dependent and to require both Rad53 and its target Dun154.  It was 
suggested that Pph3 could be a target downstream of Dun1.  Interestingly, in a 
recent large-scale proteomics screen to identify targets of DNA damage pathway 
kinases one member of PP4, Psy4, was identified as a substrate of Mec1 and/or 
Tel1, however neither Pph3 nor Psy2—the subunits essential to regulation of 
Maf1—was identified as a substrate of either Mec1, Tel1, Rad53 or Dun155.  It is 
possible that other members PP4 are also targets of one of these kinases, since 
the screen was not saturating.  Or, alternatively, a target of Dun1 could 
potentially regulate PP4 in response to DNA damaging reagents.  In the likely 
scenario that PP4 is acting downstream of Rad53 in regulating Maf1, there arises 
the intriguing idea that PP4 could act in a feedback loop where Rad53 activates 
PP4 for dephosphorylation of Maf1, after which PP4 inactivates Rad53 to exit 
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from the DNA damage checkpoint28, thus allowing Rad53 to be active only 
transiently.  
Perspectives on Maf1-Pol III Fusion Action 
While this manuscript was in preparation, the co-structure of Maf1 with 
yeast Pol III was solved14, which provides interesting insights into the mechanism 
of action of the Maf1-Rpc160 fusion construct.  The co-structure showed that 
Maf1 indeed binds to the complex in a manner to interact with the clamp domain 
of Rpc160 (aa 1-245).  Therefore, Maf1 fused to the amino-terminus of Rpc160 is 
an ideal position to poise the complex for repression.  In the crystal structure, it 
was determined that binding of Maf1 to Pol III causes a shift in the position of the 
C34 subunit within the complex that does not permit Brf1 to bind, effectively 
inhibiting Pol III from binding to TFIIIB-containing promoters.  Other structural 
studies of Maf1 protein have shown that the phosphorylated form of Maf1 is 
correlated with absence of interaction between its amino-terminal A domain and 
its carboxyl-terminal BC domain, while dephosphorylation is correlated with their 
interaction56.  This suggests that dephosphorylation helps to create a more 
compact Maf1 that could bind in the pocket between C34 and C82 in the Pol III 
complex.  These results can help us understand how the fusion growth defect is 
seen at variable levels.  As shown in the results, induction of the fusion protein in 
WT strain by galactose causes slower growth than normal (Fig. 3.1D).  However, 
if a condition of stress, such as 10 nM rapamycin, is added to galactose plates, 
this causes the cells to arrest completely (data not shown).  Alternatively, the 
fusion growth defect can be attenuated by deletion of the phosphatase.  These 
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results can be explained by the idea that Maf1 in the fusion context is 
dephosphorylated and binding more strongly to the complex than usual, inhibiting 
interaction with TFIIIB, which is required for transcriptional initiation and 
reinitiation.  In the same light, in the phosphatase mutant, Maf1 is not 
phosphorylated, so the A and BC domains are not interacting, and Maf1 doesn’t 
bind in a way that occludes Brf1 association, leading to normal Pol III activity and 
growth.  Based on this interpretation, the Maf1-Rpc160 fusion provides a strong 
genetic test for the involvement of a factor in regulation of Maf1 phosphorylation 
by monitoring the colony size phenotype on galactose-containing plates of 
mutants harboring the fusion.  By this manner, we also determined some of the 
accessory factors that are most likely acting with PP4 to dephosphorylate Maf1 
(e.g., Tip41 and Rrd1).  It will be interesting to use this tool to look for other 
activators and repressors of Maf1 phosphorylation and Pol III activity, or to 
further investigate the mechanism of repression by Maf1.   
Materials and Methods 
Growth Conditions 
We used standard culture methods.  See Table 3.1 for strains used.  All 
strains were S288C background unless indicated.  For monitoring 
phosphorylation status of Maf1, we grew initial cultures to OD600 ~0.5–0.7 (T=0), 
after which we applied a stress treatment.  We added cycloheximide (5 ug ml-1) 
to cultures 5 min prior to application of stress treatment, unless otherwise 
indicated.  Stress treatments are as follows: rapamycin (125 nM, Sigma); methyl 
methane-sulfonate (0.13%, Sigma); chlorpromazine (250 uM, Sigma); nutrient  





Strain Genotype Source 
YBC1894 his3!1 leu2!0 met15!0 ura3!0 MATa Ref. a 
YBC1895 his3!1 leu2!0 lys2!0 ura3!0 MAT" Ref. a 
YBC2026 his3!1 leu2!0 lys2!0 ura3!0 maf1!::KanMX MAT" Ref. a 
YBC2077 ura3-52 trp1#63 his3#200 leu2::PET56 RPC82-13$Myc MAF1-
3$HA::KanMX MAT# 
Ref. b 
YBC2600 his3!1 leu2!0 met15!0 ura3!0 pph3!::KanMX MATa Ref. a 
YBC2699 his3!1 leu2!0 met15!0 ura3!0 pph21!::KanMX MATa Ref. a 
YBC2784 ade2-1 his3-11, 15 le2-3, 112 trp1-1 ura3-1 lys2-953 pph22-
172::URA3 pph21!1::HIS3 pph3!1::LYS2 can1-100 ssd1-d2 
Gal+ MATa 
Ref. c 
YBC2831 his3!1 leu2!0 ura3!0 RPC160 Gal+ p2265 MATa This study 
YBC2833 his3!1 leu2!0 ura3!0 rpc160!::KanMX Gal+ p2265 MATa This study 
YBC2846 his3!1 leu2!0 met15!0 ura3!0 psy2!::KanMX MATa Ref. a 
YBC2847 his3!1 leu2!0 met15!0 ura3!0 psy4!::KanMX MATa Ref. a 
YBC2920 his3!1 leu2!0 met15!0 ura3!0 rts1!::KanMX MATa Ref. a 
YBC2932 his3!1 leu2!0 met15!0 ura3!0 cdc55!::KanMX MATa Ref. a 
YBC2934 his3!1 leu2!0 met15!0 ura3!0 psy2!::KanMX MAT" This study 
YBC2939 his3!1 leu2!0 met15!0 ura3!0 tpd3!::KanMX MATa Ref. a 
YBC2940 his3!1 leu2!0 met15!0 ura3!0 pph21!::KanMX 
pph22!::KanMX MAT" 
This study 
YBC3000 ura3-52 trp1#63 his3#200 leu2::PET56 RPC82-13$Myc MAF1-
3$HA::NatMX MAT# 
This study 
YBC3048 his3!200(his3!1) ura3-52(ura3!0) trp1!63(TRP1) 
leu2::PET56(leu2!0) RPC82-13xMyc::TRP1 MAF1-3xHA::NatMX 
pph3!::KanMX MAT" 
This study 
YBC3083 his3!1 leu2!0 met15!0 ura3!0 ppm1!::KanMX MATa Ref. a 
YBC3086 his!1 leu2!0 met15!0 ura3!0 psy2!::KanMX psy4!::KanMX 
MAT" 
This study 
YBC3109 his3!1 leu2!0 met15!0 ura3!0 rrd1!::KanMX MATa Ref. a 
YBC3110 his3!1 leu2!0 met15!0 ura3!0 rrd2!::KanMX MATa Ref. a 
YBC3111 his3!1 leu2!0 met15!0 ura3!0 tip41!::KanMX MATa Ref. a 
YBC3429 his3"1 leu2"0 met15"0 ura3"0 PSY2-GFP::His3MX MATa Ref. d 
YBC3430 his3"1 leu2"0 met15"0 ura3"0 PPH3-GFP::His3MX MATa Ref. d 
YBC3146 ade2-1 can1-100 his3-11,15 leu2-3,112 trp1-1 ura3-1 PPH3-
TAP::KanMX MATa (W303) 
Ref. e 
YBC3147 ade2-1 can1-100 his3-11,15 leu2-3,112 trp1-1 ura3-1 PSY2-
TAP::KanMX pph3!::HIS5 MATa (W303) 
Ref. e 
a. Research Genetics (Invitrogen).   
b. Roberts, D.N., Wilson, B., Huff, J.T., Stewart, A.J. & Cairns, B.R. Mol Cell 22, 633-44 
(2006). 
c.  Evans D.R. & Stark M.J. Genetics 145, 227-41 (1997). 
d.  Invitrogen. 
e.  O’Neill B.M., et al., Proc Natl Acad Sci U S A 104, 9290-5 (2007). 




deprivation (0.15$ SC, no glucose); glucose deprivation (1$ SC, no glucose); 
glycerol (1$ SC, 2% glycerol); amino acid deprivation (1$ synthetic defined 
medium containing auxotrophic amino acids only); phosphate deprivation 
(synthetic complete made without nitrogen base mix [Difco], re-adding 
ammonium sulfate, biotin, calcium pantothenate, inositol, all trace elements, 
magnesium sulfate, magnesium chloride, sodium chloride, and calcium chloride 
but not potassium phosphate)57; nitrogen limitation (synthetic complete made 
with sodium sulfate instead of ammonium sulfate); dithiothreitol (5 mM).  At 
harvest, we cross-linked cells for 15-30 min in 1% formaldehyde at room 
temperature (RT, 23 °C), and washed them three times with cold TBS.  For co-
immunoprecipitation (co-IP), we grew cultures to OD600 ~1 and did not cross-link 
them, unless otherwise indicated.  For Northern blot, we grew cells to OD600 
~0.5–0.7, then applied treatment.  We froze cells in liquid nitrogen, or prepared 
extracts immediately.  For fusion growth assay spot dilutions, we prepared 
overnight cultures in SC plus glucose and spotted to plates with glucose, 
galactose, and/or 5-fluoroorotic Acid (FOA).  We incubated plates RT 4–6 days, 
until the size of control colonies (i.e., those containing plasmid p2266 or p518) 
was equivalent between strains. 
Extract Preparation, Co-immunoprecipitation 
and Western Blot 
For Maf1 phosphorylation Western blot and cross-linked co-IP, we broke 
cells with 1 mm glass beads in ChIP lysis buffer12, sonicated six times for 30 s on 
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highest setting, and clarified by centrifugation.  For noncrosslinked co-IP, we 
prepared extracts in a similar manner, except using lysis buffer (50 mM Tris-HCl 
pH 7.5, 200 mM NaCl, 0.1% Triton, 1 mM EDTA, 10% glycerol, 0.1 mM DTT and 
protease inhibitors) and no sonication.  We incubated protein concentration with 
Biorad assay and loaded equal protein amounts (usually 30 ug per lane).  For co-
IP, we incubated 40 ul Dynabeads (preincubated with BSA plus 2 ug anti-HA 
[12CA5] antibody) or FLAG-agarose beads (Sigma) with 1 mg of extract for 4–6 h 
at 4 °C, eluted with 2$ sample buffer or FLAG peptide (Sigma), and used half of 
the eluate for Western blot.  For Maf1 phosphorylation Western blot, we used 
10% gels with a 1:125 bis-acrylamide ratio.  We performed Western blot with 
anti-HA antibody (12CA5 or Abcam 9110), anti-FLAG (Sigma), or anti-Myc 
(9E10).   
Northern Blot 
We isolated RNA and performed Northern blot as described12, using 20 ug 
per lane and overnight hybridization with end-labeled probes.  Blots were 
exposed to phosphoimager screen for 24 h, scanned, and the images were 
quantified using ImageQuant. 
Fluorescence Microscopy 
We performed immunofluorescence for Maf1 as described12.  We treated 
live Psy2-GFP yeast cells with Hoechst to stain nuclei and visualized with 
confocal microscope.   
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In Vitro Dephosphorylation Assay 
We purified yeast 6xHis-Rad53 from BL21 codon plus electro-competent 
E. coli as described58.  We pooled Rad53 fractions, diluted in storage buffer (50 
mM Tris, pH 7.5, 250 mM NaCl, 30% glycerol), concentrated, and repeated.  We 
stored aliquots at -80 °C.  We isolated phosphorylated Maf1 by galactose 
induction in pph3" strain containing p2811.  We diluted overnight cultures 
containing 2% raffinose, 0.1% glucose into 4 L of medium with 1.5% raffinose 
(OD600 ~0.06) and incubated RT for 8 h.  We induced cultures with 2% 
galactose (OD600 ~1.584) for 4 h and YPGal 2% (1:4 ratio) for one additional 
hour.  To induce increased phosphorylation of Maf1, we added glucose to 2% 
final concentration and incubated for 1 h.  We harvested the cells by 
centrifugation, freezing in liquid nitrogen and breaking by pulverizing in liquid 
nitrogen bath.  Cell powder (~10 g) was lysed in 30 ml lysis buffer (50 mM Tris 
pH 7.5, 300 mM NaCl, 0.1% NP-40, 10 mM imidazole, 1 mM BME, 5% glycerol 
and protease inhibitors (PIs)).  We centrifuged lysate to clarify and incubated with 
200 ul pre-washed Ni2+ beads for 3 h, washed twice with nickel wash buffer (20 
mM Tris pH 7.5, 250 mM NaCl, 5% glycerol, 20 mM imidazole, 1 mM BME), and 
eluted with wash buffer containing 300 mM imidazole.  We pooled the fractions, 
diluted them with storage buffer, concentrated, and repeated.  We stored aliquots 
at -80 °C.  For Pph3-TAP and Psy2-TAP pph3" complex preparation, we diluted 
starter YPD cultures containing 200 ug ml-1 G418 into 2L 2$ YPD with 4% 
glucose (OD600 ~0.3), incubated for 9 h (OD600 ~1.3), harvested by 
centrifugation and frozen in liquid nitrogen.  We broke cells (~15 g per strain) by 
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pulverizing in liquid nitrogen bath and stored powder at -80 °C.  For one 
experiment, we lysed 3 g of cell powder in 25 ml lysis buffer (50 mM Tris pH 7.5, 
250 mM NaCl, 5% glycerol, 2 mM EDTA, 1% NP-40, PIs).  We centrifuged lysate 
to clarify, we reduced NaCl to 150 mM, and incubated with 100 ul prewashed IgG 
bead slurry for 5 h.  We washed IgG-bound complexes three times in 50 ml wash 
buffer (same as lysis, except 150 mM NaCL and no EDTA or PIs), and once with 
700 ul reaction buffer (25 mM Tris pH 7.5, 100 mM NaCl, 5 mM MnCl2 0.5 mM 
DTT).  We mixed reactions with 10 ul of IgG-bound complex (or 2 ul lambda 
phosphatase) and 5 ul of Rad53 or Maf1 substrate, brought to 50 ul with reaction 
buffer.  We incubated the reactions on rotator at RT for 2 or 8 h, then quenched 
with 25 ul 4$ SDS loading buffer and stored at -20 °C.  Half of each reaction was 
loaded per lane.  We made 7.5% (for Rad53) or 10% (for Maf1) gels with 1:125 
bis:acrylamide.  Western blot image was scanned and analyzed using 
ImageQuant.  The Pph3-TAP and Psy2-TAP preparations contain proteins that 
cross-react with the anti-HA antibody at the approximate size of 
dephosphorylated Maf1 when either is alone in a lane (e.g., Fig. 3.6E, lanes 2–3, 
top panel), but since the total signal from HA antibody is unchanged when 
combined with either complex (lanes 6, 8), this background signal has a minimal 
effect on the signal of the combined reactions.  We calculated enzyme activity by 
determining the percent of the bottom band (indicated by lambda phosphatase 
reaction, Fig. 3.6E, lane 4) as a fraction of the total signal for each lane.  We set 
the difference between the percent for lambda and the percent for 
phosphorylated Maf1 (Fig. 3.6E, lane 1) to 100% and we adjusted the 
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bottom/total percentages for each enzyme+substrate reaction accordingly.  We 
expressed the percent of lambda phosphatase activity as the average of two 
replicates with standard error of the mean as confidence interval.   
Plasmid Construction 
We amplified the 3xHA tag from p2217 with oligos BC3359 and BC3360 
and ligated into p521 XhoI and XmaI sites to create plasmid p2264.  Plasmid 
p2264 contains a polylinker that has sites not found in MAF1 or RPC160 (i.e., 
Met25 promoter, then polylinker—XbaI, SpeI, BamHI, XmaI, SacII, AvrII, SalI, 
NotI—then 3XHA, XhoI, Cyc1 terminator), derived from BC3359.  We amplified 
the coding region of RPC160 from genomic DNA with BC3361 and BC3362 and 
ligated into p2264 SalI and NotI sites to create p2265.  We inserted the XmaI-
XhoI fragment containing RPC160-3xHA into p528 to create p2266 (expression 
under control of GAL1 promoter).  We amplified MAF1 from p1863 with oligos 
BC3363 and BC3364 and inserted into p2266 SacII and AvrII sites to create 
p2268.  We inserted annealed oligos BC3432 and BC3433 at a 1:2 ratio of 
vector:insert into AvrII and SalI sites of p2268 to create p2320; we used oligos 
BC2552 and BC3405 to confirm that only one copy was inserted.  We amplified 
the coding region of PPH3 from genomic DNA with BC3534 and BC3430, 
BC3531, BC3532, or BC3533 and ligated into p518 BamHI and EcoRI sites to 
create p2352, p2353, p2354, and p2355, respectively.  We inserted the same 
PPH3 fragments into p522 BamHI and EcoRI sites to create p2356, p2357, 
p2358, and p2359, respectively.  We created p2424 by site-directed mutagenesis 
(SDM) with BC2883, BC2884 in p2268, followed by subcloning SacII-AvrII 
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fragment into p2266.  We created p2425 by sequential SDM with BC2549 and 
BC2552 and then with BC2883 and BC2884, followed by subcloning SacII-AvrII 
fragment into p2266.  We created p2531 by amplifying PSY2 coding region (plus 
750bp upstream) from genomic DNA with BC3848 and BC3849 and ligating into 
p7 SacII and BamHI sites along with PacI-BglII fragment from p709 (HA tag plus 
Adh1 terminator).  We created p2811 by SDM of p1625 with oligos BC5163 and 
BC5164 to add 10 histidine residues between Maf1 coding region and the first 
HA tag.  All thermo-cycler-amplified fragments were confirmed after insertion by 
sequencing.  See Table 3.2 for a list of plasmids and Table 3.3 for a list of oligos. 
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Plasmid Description Source 
p7 pRS315 Ref. a 
p8 pRS316 Ref. a 
p709 pFA6a:3HA:KanMX6 Ref. b 
p521 p416.MET25 (FB1521) Ref. c 
p518 p413.MET25 (FB1518) Ref. c 
p528 p415.GAL1 (FB1528) Ref. c 
p1625 pRS416.GAL1prom.MAF1-4HA Ref. d 
p1841 316.MAF1-4HA.4 or maf1-104 Ref. e 
p1863 316.MAF1.4HA Ref. e 
p2217 pMaf1(#50-139).3XHA Ref. f 
p2264 521.MET25.3XHA This study 
p2265 521.MET25.RPC160.3XHA This study 
p2266 528.GAL1.RPC160.3XHA This study 
p2268 528.GAL1.MAF1.RPC160.3XHA This study 
p2276 pRS315-PPH21-HA Ref. g 
p2279 pRS316-Myc-TPD3 Ref. g 
p2320 528.MAF1.linker.RPC160.3XHA.1 This study 
p2352 413.PPH3.Met25.CEN This study 
p2353 413.PPH3.FLAG.Met25.CEN This study 
p2354 413.PPH3.FLAG.NES.Met25.CEN This study 
p2355 413.PPH3.FLAG.NLS.Met25.CEN This study 
p2356 413.PPH3.Met25.2u This study 
p2357 413.PPH3.FLAG.Met25.2u This study 
p2358 413.PPH3.FLAG.NES.Met25.2u This study 
p2359 413.PPH3.FLAG.NLS.Met25.2u This study 
p2424 528.maf1-124.RPC160.3XHA This study 
p2425 528.maf1-104.RPC160.3XHA This study 
p2531 315.PSY2.3HA.CEN This study 
p2645 pET-Rad53 Ref. h 
p2811 Gal1-Maf1-10xHis-HA This study 
a. Sikorski R.S. & Heiter P. Genetics 122, 19-27 (1989). 
b. Longtine M.S. et al., Yeast 14 953-61 (1998). 
c.  Mumberg D, Müller R, Funk M. Nucleic Acids Res 22, 5767-8 (1994). 
d.  Constructed by Jason Huff & Brad Cairns, unpublished. 
e.  Roberts, D.N., Wilson, B., Huff, J.T., Stewart, A.J. & Cairns, B.R. Mol Cell 22, 
633-44 (2006). 
f.  Constructed by Boris Wilson & Brad Cairns, unpublished. 
g.  Gift from David Virshup. 
h.  O’Neill B.M., et al., Proc Natl Acad Sci U S A 104, 9290-5 (2007). 
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SUMMARY AND PERSPECTIVES 
Human RNA Polymerase III 
Human Pol III Transcriptomes  
The studies in this work were motivated by the need for a comprehensive 
view of the Pol III transcriptome in human cells and the need to understand key 
mechanistic steps of the regulation of Pol III transcriptional activity.  To 
understand the breadth of Pol III transcription in human cells, we performed 
ChIP-seq of multiple Pol III factors in multiple cell types.  We saw strong 
evidence for cell-type-specific expression of multiple genes, with normal cells 
showing fewer active genes (e.g., foreskin fibroblasts, 168 genes) and 
transformed cells showing more active genes (e.g., HEK293T, 336 genes).  To 
investigate the potential reasons for differences in enrichment of the Pol III 
machinery, we compared active and inactive genes with chromatin ChIP-seq 
profiles in two cells types and found that active genes were associated with 
positive chromatin modifications (e.g., H3K4me3) while inactive genes lacked 
positive chromatin modifications and had higher levels of repressive 
modifications (e.g., H3K27me3), suggesting a chromatin regulatory component in 
Pol III occupancy.  We also characterized the interesting association of Pol II at 
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Pol III genes.  Active Pol III genes are frequently found in promoters of Pol II 
genes (proximal) and outside of annotated Pol II promoters (distal), Pol II 
enrichment is at similar levels.  These distal sites are characterized by active 
chromatin and enrichment of transcription factors, and may represent a special 
type of Pol II promoter or enhancer.  We also identified several novel Pol III 
genes based on enrichment of Pol III machinery, chromatin status, RNA-seq 
expression data and Pol II enrichment.  It will be interesting to characterize these 
novel transcripts further.  This would involve identifying whether they are part of 
ribonucleoprotein complexes, determining whether the expression is restricted to 
particular tissues, and determining whether these transcripts play a role in cancer 
progression.  Notably absent among our findings of active Pol III genes were the 
previously reported miRNAs produced from the chromosome 19 miRNA cluster 
(C19MC)1.   
New Ideas About Pol III and Pol II Regulation 
The human Pol III transcriptome study presents new ideas about Pol III 
regulation in relation to Pol II regulation.  We found a statistically high correlation 
between Pol III occupancy and Pol II occupancy genomewide.  In both distal and 
proximal sites, high levels of positive chromatin indicative of a Pol II promoter 
were present.  The result solicits the question of whether Pol III is responsible for 
Pol II recruitment or vice versa.  Pol III could require transcription factors and Pol 
II activity to open up the chromatin environment by recruiting histone modifiers 
that place H3K4me3 and other positive chromatin marks, thus permitting Pol III to 
gain access to these genes.  Alternatively, Pol III transcription in this region could 
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open up the chromatin by its ability to displace nucleosomes over the body of the 
gene, thereby allowing opportunistic binding of Pol II transcription factors, which 
then recruit Pol II and its accompanying chromatin modifiers.  In the latter model, 
the reason for choice of active genes in each tissue is unexplained.  The 
question is whether Pol II activity and basal machinery is required for recruitment 
of Pol III. This will be an important question to address in future studies.  Simple 
inhibition of Pol II is confounding, since disruption of Pol II in the cell can have a 
major impact on the cellular processes in the cell, which would most likely lead to 
a stress response that could cause indirect repression of Pol III.  In order to 
address this, it will be important to isolate a Pol II/Pol III distal unit and restrict 
access by Pol II to this unit alone (and not the rest of the genome), and test for a 
change in recruitment of Pol III.   
Another important aspect of Pol II and Pol III regulation that deserves 
further study is the influence of active Pol III genes upon nearby Pol II genes.  
Approximately 20% of active Pol III genes are found in a promoter of an 
annotated Pol II gene, but whether the activity of one can regulate the activity of 
the other in these particular examples is not known.  To address this, specific 
repression of a particular Pol II gene, containing a Pol III gene within its 
promoter, by siRNA could be performed and expression of the Pol III gene could 
be monitored.  Alternatively, global repression of Pol III could be performed with 
a specific inhibitor (e.g., ML-60218, Calbiochem) and expression of Pol II genes, 
containing Pol III genes within their promoters, could be monitored.  An important 
characteristic of these promoters that should be considered when studying the 
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regulation of these shared promoters is the fact that 70% are in a divergent 
orientation, while 30% are arranged so that the Pol III gene is expressed from the 
same strand as the Pol II gene.  It would be interesting to see whether Pol III 
expression in one orientation (e.g., same strand) might be repressive for Pol II 
gene expression, while expression in a separate orientation (e.g., divergent) 
might be activating or neutral for Pol II gene expression.   
Cell Type-specific Pol III Gene Expression 
Related to the regulation of Pol II with Pol III is the phenomenon of cell 
type-specific, or tissue-specific, regulation of Pol III gene expression.  Is this a 
cause of variability in expression of Pol II genes with Pol III genes in their 
promoters?  This would not explain this phenomenon at distal sites that have no 
Pol II genes in the immediate vicinity, e.g., chr6 tRNA clusters, where we see the 
highest rate of tissue-specific enrichment of Pol III.  Or, it could be that these Pol 
III-bound genes are in enhancers of distant Pol II genes.  If that is the case, it 
would be interesting to identify any Pol II genes of which the Pol III units could be 
an enhancer to see if those genes are coordinately regulated with Pol III in the 
various cell types. 
Pol III “Enhancer” Class and DNA Looping 
One small but potentially important detail from our study is that Ets1 DNA 
binding sites found at distal sites were quite divergent from the consensus 
sequence, or absent.  This raises a possibility that the ChIP signal we see could 
be a shadow of Ets1 bound to DNA that has looped to this “enhancer” site.  In 
this case, the Ets1 DNA consensus site could be in the promoter of any 
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housekeeping gene, and the Pol III transcription unit, acting as an enhancer, has 
looped over to this promoter; because the DNA is in proximity to this promoter, it 
would be crosslinked to Ets1, even if Ets1 is not bound to the DNA of the Pol III 
transcription unit at all.  This would also invoke a shadow of all other elements of 
the promoter bound by Ets1 as well, including Pol II and positive chromatin 
modifications.  One way to rule out this “shadow” hypothesis would be to identify 
any transcripts produced at the location where Pol II appears adjacent to the Pol 
III gene.  Interestingly, this hypothesis involving DNA looping is another potential 
interpretation for the fact that many of the TFIIIC-only sites showed no A-box or 
B-box consensus sites2.  Incorporation of 3C (or Hi-C) technology3 in analysis of 
Pol III distal sites could determine whether the DNA at distal Pol III units is in 
proximity to another annotated Pol II gene.  
Phosphorylation of Maf1 in Regulation of Pol III 
Evidence for PP4 as the Phosphatase of Maf1 
 Since Pol III is only repressed by unphosphorylated Maf1, we sought to 
address the yet open question of the identity of the phosphatase of Maf1.  For 
this, we took a candidate approach and studied protein phosphatase 2A (PP2A) 
and protein phosphatase 4 (PP4).  We showed that yeast genetically disrupted 
for components of PP4 but not PP2A are defective for dephosphorylation of Maf1, 
nuclear accumulation of Maf1, and acute phase repression of Pol III.  We showed 
that Maf1 interacts with Pph3 and that PP4 purified from yeast is able to 
dephosphorylate Maf1 in vitro, suggesting the action of PP4 on Maf1 is direct.  
We also showed that Pph3 (the catalytic subunit of PP4) is required for 
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dephosphorylation of Maf1 in response to multiple stress conditions, suggesting 
that PP4 and Maf1 are co-integrators.   
Regulation and Activation of PP4 in Repression of Pol III 
 A central issue for the future will be how PP4 is activated to 
dephosphorylated Maf1.  It will be important to determine whether there is a 
single key step in activation of PP4 in all stresses, or whether the mechanism of 
activation of PP4 will vary by the stress condition.  Multiple factors that have 
been shown to interact with PP4, such as Tip41 and Rrd1 were also shown to 
play a role in dephosphorylation of Maf1.  It will be important to define the 
mechanism of action of these co-factors for PP4 function.  PP4 complex could be 
purified from various mutants, e.g., rrd1!, to see if and in what manner PP4 is 
deactivated in in vitro dephosphorylation of Maf1 when lacking the component.  
Rrd1 is a prolyl isomerase that acts on Pro1904 of human PP2A, which is 
conserved in yeast Pph3 as Pro184.  Rrd1 has been shown to activate all PP2A 
family phosphatases in vitro5, so it is likely that it could use a similar mechanism 
to activate Pph3 as is used to activate PP2A.  Mutation at this amino acid might 
provide further information about the mechanism of Rrd1 action.   
 Another potential mechanism for PP4 activation is phosphorylation.  Psy4 
was shown to be a target of phosphorylation in the DNA damage pathway6.  
Human PP4C was shown to gain serine and threonine phosphorylation during 
after JNK activation and concurrent with PP4 activation7.  It is possible that 
conserved residues are also functioning in yeast Pph3 to allow for activation.   
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 The physical and genetic interaction of Psy2 and Pph3 with Tip418, as well 
as the requirement of Tip41 in Maf1 dephosphorylation is intriguing as it may 
shed light on the important issue of how PP4 could be regulated by Target of 
rapamycin complex 1 (TORC1).  It is generally thought that TORC1 regulates the 
PP2A family of phosphatases, including Pph3, via phosphorylation of Tap42, 
which affects the interaction of Tap42 with the phosphatase9.  Tap42 interaction 
with the phosphatase is thought to inhibit the incorporation of the phosphatases 
into their respective holoenzymes10.  Tip41 interacts with Tap42, and it is thought 
that this interaction breaks the interaction with the phosphatase so that it can 
again incorporate into the holoenzyme, e.g., PP4.  Intriguingly, Tip41 is 
associated with the PP4 holoenzyme, since Psy2 and Psy4 were found in the 
complex with it8.  This is also true of the PP6 (Sit4) holoenzyme, since it was 
found in complex with Sap4, Sap155, and Sap185, which interact with Sit4 in the 
PP6 holoenzyme11,12.  However, Tip41 does not interact with PP2A regulatory 
subunits (e.g., Tpd3, Rts1, Cdc55), therefore it is not likely incorporating into the 
holoenzyme of PP2A.  Initial studies of Tip41 were performed in relation to Tap42 
interaction with yeast PP2A, but given these differing results, it may be that Tip41 
(and potentially Tap42 as well) has a different, unknown mode of action on PP4 
compared to PP2A.  The role of Tap42 in regulation of Maf1 is unclear.  tap42-11 
mutant yeast are resistant to rapamycin and they show no defect in 
dephosphorylation of Maf1 or Pol III repression at the non-permissive 
temperature13.  Interestingly, Tap42 also shows interaction with Rrd1 and Rrd214; 
one potential mechanism by which Tap42 could repress PP2A family 
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phosphatases is by sequestering their prolyl isomerase activators.  If Tap42 were 
sufficient to keep PP4 in an inactive state, then it would be expected that a 
mutation in Tap42 would permit PP4 to be constitutively active, thus Maf1 might 
be dephosphorylated at a greater rate.  Since Maf1 is dephosphorylated at the 
same rate in WT and tap42-11 cells13, it is likely that PP4 needs an additional 
activating signal, provided by environmental stress.  Whatever the function of 
Tap42, the ability of a tap42-11 mutant to repress Pol III is nevertheless 
consistent with PP4 being the phosphatase of Maf1. 
Maf1-Pol III Fusion as a Screening Tool 
 In our Maf1 study, we also created a Maf1-Pol III tool that could potentially 
be used to look for other players in the pathway of repression of Pol III.  This 
might include other co-activators of PP4, or factors involved in PP4-independent 
mechanisms of Maf1-dependent repression of Pol III.  There are several 
pathways that have not been clearly defined that lead to repression of Pol III, 
including the pathway to nutrient deprivation stress, which requires PKC15.  It has 
also been suggested that there might be other steps involved in execution of 
repression after Maf1 binds to Pol III, and this fusion tool might be useful in 
identifying factors responsible for this step.  To the end of performing screens 
with the fusion construct, we integrated the fusion at the Lys2 gene locus and 
isolated integrants in which the fusion growth defect was still visible on 
galactose-containing plates (data not shown).  Initial work was done to find high 
copy suppressors of the fusion growth defect combined with rapamycin (to arrest 
growth); most suppressors were members of the TORC1 signaling pathway, 
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which lead to rapamycin resistance (data not shown), but a few galactose-
specific suppressors were also identified.  One such was Rrd1; although not 
intuitive, it could be that overexpression of Rrd1 could be repressive for PP4 in 
some way, by titrating essential components, thereby inhibiting Maf1 from being 
dephosphorylated.  The screen was not saturated, and it should be redesigned in 
order to avoid off-target suppressors, such as the rapamycin suppressors we 
found.  One way to potentially avoid this is to perform the screen with a low 
concentration of rapamycin and MMS (in galactose-containing plates), as it would 
be more difficult to find suppressors of both rapamycin and MMS, so suppressors 
would more likely be related to the fusion.  We also showed that Maf1 can be 
mutated in the fusion context to relieve the fusion growth defect, so another type 
of screen would be to mutate the Maf1 sequence in the fusion context by PCR 
mutagenesis to identify other key residues in Maf1 function.  
PP4 as a Potential Human Maf1 Phosphatase 
 It is noteworthy that PP4 has many conserved functions including 
dephosphorylation of !H2AX in the DNA damage response from human to yeast.  
It would be interesting if PP4 were also important for dephosphorylation of Maf1 
in human cells.  Future studies in human Pol III regulation will show whether PP4 
is the major phosphatase of human Maf1.   
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